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 ABSTRACT 
Amplification of the MYCN gene is common to many types of infancy cancer of mostly 
neuroendocrine origin, including neuroblastoma (NB). Since identification of the 
correlation between MYCN status and poor NB prognosis, many efforts have been made to 
develop efficient MYCN targeting drugs. The rationale for choosing MYCN as a 
therapeutic target for NB treatment lies in its restricted spatial and temporal expression 
related to the early stages of embryonic development and its undetectable levels in adult 
tissue. Moreover, it is found deregulated in highly malignant cancers.  
As the other MYC oncoproteins, MYCN forms a functional transcription factor when 
associated with another basic helix-loop-helix-leucine-zipper BHLHz protein named MAX 
and carries out its functions as a positive modulator of gene involved in proliferation and 
self-renewal. Together with MYCN, MAX belongs to an extended network of transcription 
factors which interact with each other binding DNA and regulating transcription of target 
genes. Thus, MYCN transcriptional activation is dependent on MAX availability. On the 
other hand, repressive side of the network is represented by MNT-MAX dimers which 
repress transcription of MYCN target genes. 
In this thesis, two approaches have been adopted to antagonize the oncogenic features of 
MYCN-overexpressed NB cells. 
A first genetic approach is based on the modulation of the expression levels of MAX and 
MNT network proteins. Published gene arrays on Kocak dataset cohort of 643 patients 
highlight that low levels of MYCN antagonists MAX and MNT in presence of MYCN 
amplification, are related to good clinical outcome. Using RNA interference in MYCN-
amplified cells, we have demonstrated that downregulation of MAX and MNT affects in 
first instance cell proliferation. Moreover, using retinoic acid treatment, it has been 
demonstrated that knockdown of MAX and MNT promotes neuronal differentiation and 
induces both expression of positive prognostic markers and downregulation of negative 
ones. Thus, suppression of the malignant phenotype after MAX and MNT silencing has 
been confirmed. 
On the other hand, same Kocak dataset pointed out the correlation between high levels of 
MAX and MNT and short term survival probability in MYCN amplified NB patients. 
Using transient transfection of MYCN-amplified cell lines, the correlation between high 
 MYCN antagonist levels and the enhancement of the malignant phenotype has been 
confirmed. In this first part of the work, it has been established that it is not the unique 
MYCN amplification to exactly reflect the biology of NB, but MYCN functions are 
strongly related to the expression of MYC/MAX/MXD network proteins. 
 
To date, despite the attractiveness of MYCN as a therapeutic target and the discovery of 
new MYCN targeting compounds, most of these drugs have not passed the pre-clinical 
stage because of their non-specificity or selection of resistant clones. A second approach to 
counteract MYCN oncogenicity has been proposed and a novel iron chelator M606 
derivative of hydroxyquinolones was identified for its ability to downregulate MYCN only 
in actively proliferating cells. Moreover, characterizing M606 action on MYCN promoter, 
deregulation in E2F/RB pathway has been found. 
Through chromatin immunoprecipitation, it was highlighted the role of deacetylation and 
not methylation in mediating MYCN downregulation. E2F1 and E2F2 consensus have 
been found necessary to induce M606-mediated downregulation of a reporter gene under 
control of MYCN promoter. 
Activator E2F family are proteins involved in cell cycle regulation and their activity is 
strictly related to RB phosphorylation state. We further pointed out the role of M606 in 
inducing hypophosphorylated state of RB supporting the hypothesis of RB sequestration of 
E2F transactivation domain, thus resulting in downregulation of E2F target genes such as 
MYCN. Same results were obtained using Exjade, an iron chelator used in NBs clinical 
trial provide evidence for a general mechanism related to iron chelator compound family. 
Studies have revealed E2F/RB pathway involvement in the negative regulation 
of MYCN induced by TGFβ and via RT-qPCR it has been suggest a putative role of TGF 
cytokine family in mediate M606 downregulation. Thus, in this part of the work M606 
action has been characterized and through comparison with Exjade, lines of evidence of 
deregulated E2F/RB pathways in Neuroblastoma have been further provided. 
 
Overall, the present results support the possibility to offset MYCN driven oncogenesis 
through genetic or pharmacological approaches. 
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1 Neuroblastoma 
1.1 Clinical and Biological Characteristics of Neuroblastoma 
Neuroblastoma (NB) is an embryonal malignant solid tumor of the sympathetic nervous 
system. It is the most frequently diagnosed neoplasm during infancy, characterized by a 
median age at diagnosis of 19 months but more than 90% of the diagnosed cases are 
children aged less than 5 years [1].  
The tumor often grows rapidly and there is a direct correlation between age and extent of 
disease. In almost half of all patients at the time of diagnosis, the disease has already 
metastatized to the bone marrow, liver, cortical bone, skin and the lymph tissue and it is 
usually refractory to chemotherapy [2]. 
It is the second most frequent extracranial malignant cancer occurring in childhood after 
leukemia and, among the various solid tumors of infancy, after those affecting the central 
nervous system, it is the most common (8-10%), with an incidence of 10.5 cases per 
million per year [3]. 
Neural crest-related precursor cells are the presumptive source of this neoplasm: this 
transient population of cells produces multipotent progenitor cells that migrate and give 
rise to the enteric nervous system, the peripheral nervous system, pigment cells, Schwann 
cells, and cells of the craniofacial skeleton and adrenal medulla [4]. 
Given the wide lineage these cells can give rise to, the tumor can arise anywhere along the 
sympathetic chain concurring to the heterogeneous histology and pathology of NB. 
Fig.1. Neural crest migratory pathways. Sdssdcsdcsdvd 
Left, Pathways in the early embryo. Red arrows indicate the first 
emigrating cells which follow the ventral sympathoadrenal line. 
Purple arrow highlights the second wave of emigrating cells (pathway 
2) that follows the ventrolateral pathway. Pathway 3 indicated by the 
green arrow underlines the last cells that leave the neural tube and 
through the dorsolateral pathway, go on to differentiate into pigment 
cells.  
Right, Cells originate after migration of neural crest cells [4]. 
 
 
Most primary tumors (65%) appear to arise in the abdomen especially in the medullary 
region of the adrenal glands and in the extra-adrenal paraspinal ganglia followed by the 
mediastinum [3]. Thus, NB is thought to be preferentially a sympathoadrenal lineage 
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neural crest-derived tumor. Less common sites are the sympathetic ganglia in the neck, 
head, chest and pelvis [5]. 
Given its origin, the disease has overall a broad spectrum of clinical features directly 
related to the site, extent and biological features of the primary tumor and the presence of 
metastasis [6]. Cancer grade is directly correlated to degree of cellular and extra-cellular 
maturation: in children with a median age of less than 2 years the most undifferentiated 
and aggressive NB form is commonly found, while ganglioneuroma, the more mature 
tumor type, affects older age groups [6]. During the past years, a significant enhancement 
in survival probability of low risk NB patients has been achieved, but for what concerns 
high-risk clinical phenotype patients, long term survival is still less than 40% [7]. 
However, because of unexpected clinical behaviors of this tumor, such as maturation or 
spontaneous regression in some patients and lethality prior to reproductive age in others, it 
is possible to observe different clinical pictures at the onset of NB: 
Localized tumors: about 40% of patients has a localized accidentally discovered disease 
that usually respond to chemotherapy and/or surgical removal.  
Metastatic disease: about half of the patients have hematogenous metastasis, the spread of 
the primary tumor into adjacent lymph nodes is less common [3]. 
4S disease: in 1971 D’Angio and colleagues first described this distinctive condition with a 
case study on 5% of patients. The primary tumor has reduced dimensions with various 
metastasis that spontaneously regress. Interestingly, among all tumors, NB is characterized 
by the highest percentage (5-10%) of spontaneous regression or differentiation into 
ganglioneuroma without pharmacological treatment [8]. Given these clinical data, 
comprehension of molecular mechanisms underlying spontaneous 
regression/differentiation may advantage therapeutic approaches to drive these phenomena. 
1.2 Clinical Prognostic Indicators: Grading and Staging 
Clinical staging, essential to help predict outcome and select suitable therapy, classifies 
patients into high, intermediate and low risk groups based on: 
Age: the main prognostic factor, inversely related to outcome and independent of tumor 
stage [9]. 
International Neuroblastoma Pathology Classification (INPC): after revision of the 
original Shimada system, it describes four categories of NB patients divided for their 
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degree of neuroblastic maturation toward ganglion cells, schwannian stromal development 
and mitosis-karyorrhexis index (MKI):  
• Neuroblastoma Schwannian stroma-poor with variable histology, consisting of a large 
population of small poorly differentiated or differentiating neuroblasts  
• Ganglioneuroblastoma intermixed Schwannian stroma-rich with a favorable histology, 
consisting of low-malignancy ganglion cells capable to metastasize  
• Nodular ganglioneuroblastoma, both Schwannian stroma-rich or poor characterized by 
favorable or unfavorable histology 
• Ganglioneuroma, benign form characterized by presence of fully mature ganglion cells 
and predominance of dense stroma of Schwann cells [10]. 
Fig.2.  Differentiation grade in NBs. 
A, Black arrows indicate ganglion and Schwann cells, 
peculiarity of stroma-rich NBs. 
B, Stroma-poor NB consists of densely packed small 
round blue cells with small cytoplasm [3]. 
Tumor stage International Neuroblastoma Staging System: the currently used system 
based on degree of surgical excision of primary tumor and involvement of lymph nodes 
(Tab.1) [8]. 
 
          Table 1. International Neuroblastoma Staging System [8]. 
 
Biological manifestations (i.e. MYCN amplification and DNA ploidy): there is a 
reproducible correlation between a high MKI and presence of adverse clinical and 
biological manifestations [11]. 
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1.3 Genetic Abnormalities in NB and Biological Prognostic Indicators 
Neuroblastoma displays profound genetic heterogeneity that reflects the possibility to run 
into different tumor subtypes that range from spontaneous regression to rapid progression 
and death.  
While its anatomic pattern of origin is well defined, the etiology of NB remains still 
unclear and even though the majority of cases appear to be sporadic, there are lines of 
evidence of hereditary NB. 
Familial genetic lesions: Hereditary NB is both rare and heterogeneous and occurs in less 
than 5% of all NBs. This minor subset of patients inherits a genetic predisposition to 
disease that follows an autosomal dominant inheritance pattern with incomplete penetrance 
and is related to germ-line mutations in the short arm of chromosome 16 (16p12-13), 
though, to date, no causal genes have been characterized [12,13]. 
Germline mutations in paired-like homeobox 2B (PHOX2B) on chromosome 4p13, are the 
first specific predisposition mutations identified in NB; this gene is a regulator of 
autonomic nervous system development and it is expressed early in the developing 
sympathoadrenal progenitors promoting neuron formation and differentiation. Mutations in 
PHOX2B were found in about 7% of familial NB cases and only 2% of total cases 
suggesting that these mutations could give selective advantages to tumor cells but they are 
likely not sufficient to drive NB pathogenesis [14].  
Other germline mutation commonly found in familial NB cause activation of ALK 
signaling. Anaplastic lymphoma kinase ALK (Ch. 2p23) is a member of receptor tyrosine 
kinases and is thought to have a role in the normal development of the central and 
peripheral nervous system. De Brouwer et al demonstrated that these mutations are found 
in similar frequencies in favorable and unfavorable outcome cases and occur in about 50% 
of familial NB cases but also 12% of sporadic NB cases [15]. Concordance in mutation 
patterns for NB in twins during childhood indicates the predominance of hereditary factors 
in tumorigenesis, whereas discordance in older twins underline the crucial role of random 
mutations and/or other factors [16-17]. 
Sporadic NB may also show a germline contribution, with greater effect sizes for rare 
pathogenic variants. Genome-wide association studies have allowed the identification of 
risk polymorphisms in several large independent studies. Maris and colleagues 
characterized three common SNPs within two overlapping genes, FLJ22536 and FLJ44180 
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at 6p22 locus: high-risk NB and low patient survival was significantly associated with 
homozygosity for any of these risk alleles. Association with high-risk NB was found also 
for the low frequency germline variants of BRCA1-associated RING domain1 (BARD1) 
gene [14]. Heterogeneity of the disease suggests that pattern of acquired genetic alterations 
defines the tumor phenotype: it has been found that somatic change such as change in 
tumor-cell ploidy or gain/loss of alleles and oncogene activation are the main mutations 
associated with sporadic NB development [18]. 
DNA plody: Low-stage tumors are hyperdiploid or near-triploid, usually associated with 
good prognosis and commonly found in patients of less than 1 years of age. Despite the 
clinical predictability of ploidy in infants, this prognostic significance is lost for patients 
older than 1-2 years. This is reasonably due to the presence of several structural 
rearrangements in hyperdiploid/near-triploid tumors of older patients that are absent in 
infants with whole chromosome gains [19]. 
Chromosome gain: Trisomy of chromosome 17q occurs in about half of the NB primary 
tumors. Gain of 17q is associated with tumor malignancy, poor prognosis and MYCN 
amplification but its definition as independent prognostic factor is still controversial [12]. 
Although the breakpoint of 17q varies, the aberration is often due to unbalanced 
translocations of segment 17q21-qter to the distal part of chromosomes 1p or 11q. 
Translocated genetic region could reach 20Mb of 17q counting for more than 200 genes 
and at least 30 translocation sites on 20 different chromosomes have been identified [5,3]. 
Chromosome loss and tumor suppressor genes: Loss of heterozygosity LOH of the short 
arm of chromosome 1p has been found in about 25-35% of all NBs and in 70% of the 
advanced stages [20]. It correlates both with gain of 17q and MYCN amplification and it is 
independently associated with poor clinical outcome [21]. Although the responsible 
mechanism for this aberration is still unknown, relevance of 1p LOH is underlined by 
studies indicating that transfer chromosome 1p material into human NB cells in vitro 
induce suppression of tumorigenicity and differentiation [22]. Potential candidate tumor 
suppressor genes (TSGs) in the 1p LOH span a region of about 260kb at 1p36.3 and to 
date, three putative TSGs have been identified: microRNA-34a (mir-34a), the 
chromodomain helicase DNA-binding domain 5 (CHD5) and the kinesin superfamily 
protein 1B beta (KIF1Bb) all three of these proteins with a role in cell growth [23-25]. 
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LOH of 11q has been identified in approximately 40-45% of primary tumors without 
MYCN amplification. Although it is inversely correlated with MYCN amplification, this 
aberration is related to adverse clinical features and histology resulting in a useful marker 
in determining the prognosis for MYCN-not amplified NBs [26]. Putative TSGs identified 
are H2AFAX with a role in genomic stability and CADM1 which encodes for an adhesion 
protein involved in neural cell development [27]. 
About 16-27% of NB patients show LOH of 14q without showing association with a 
precise clinical stage, suggesting that this aberration may be a universal early event during 
tumor development [28]. However, it is not the single genetic marker, but the overall 
segmental genomic profile of tumors that adds information to patient prognosis [18]. 
Abnormal expression of the neurotrophin receptor: The Trk family of neutrophin signaling 
receptors (TRKA, TRKB and TRKC) are strongly correlated with the biologic and clinical 
features of NB tumors mediating proliferation, differentiation and death via the binding of 
nerve growth factor ligands [29]. Favorable NBs show expression of both TRKA and 
TRKC. High levels of the nerve growth factor receptor TRKA in association with NGFR 
and very low/no MYCN expression, were found in favorable NBs while a novel TRKA 
splice variant promoting cell survival and angiogenesis has been found in advanced-stage 
tumors. In contrast, unfavorable MYCN amplified tumors often co-expresses the full 
length TRKB neurotrophin receptor and its ligand brain-derived neurotrophic factor 
BDNF. Interestigly, the truncated form of TRKB is expressed in some favorable NB 
tumors. These tumors also express low level of TRKC ligand neurotrophn-3 and high 
levels of TRKA [30-31]. 
Amplification of loci: Amplification with the strongest prognostic value in NB involves 
MYCN gene. It is present in approximately 20% of all cases and 40% of advanced stages 
of disease and even in patients with lower stages of disease and it is related to highly 
malignant phenotype and poor prognosis. Schwab and colleagues identified the amplified 
genetic region as a large region ranging from 100kb to 1Mb from locus 2p24 copied to 
form double-minute chromatin bodies (DMs) that are extrachromosomal circular elements 
that probably accumulate by uneven segregation during mitosis. The amplified DNA 
region can also integrate into chromosomal locus to form homogeneously staining regions 
or HSRs, typical of the cultured NB cells [5,32]. 
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Fig.3. Image of fluorescence in 
situ hybridization image of 
neuroblastomas depicting MYCN 
amplification manifested as DMs 
(A), HSRs (B), or dmins + HSRs 
(C) [33]. 
 
The significance and the relevance of MYCN amplification in NB pathogenesis was first 
established in the early 1980’s from Brodeur and Seeger that pointed out the association 
with advanced stages of disease and poor prognosis [34]. 
 
 
Fig.4. Kaplan–Meier survival curve of infants less than 1 year 
of age with metastatic NB. The 3-year event-free survival 
probability (EFS) of MYCN-not amplified NB patients was 
93%, whereas those with MYCN amplified tumor had only a 
10% EFS [5]. 
 
 
 
 
Years later, Weiss et all, revealed the overall impact of MYCN confirming that 
overexpression of MYCN alone was sufficient to initiate NB formation in mice [35]. Even 
if there is a corresponding overexpression of MYCN protein in MYCN-amplified NBs, it 
is still controversial whether MYCN protein or mRNA has prognostic significance in 
tumor lacking MYCN amplification [5]. 
However, since MYCN oncogene amplification occurs in about 20% of NBs, other factors 
may probably be involved in the early stages of tumor initiation and formation. For 
instance, ALK activation results in increased expression of MYCN transcription and 
increased stabilization of MYCN protein likely via activation of AKT and ERK. 
Furthermore, genomic localization of ALK and MYCN on chromosome 2p may explain 
their co-amplification in NBs. However, no NB has been shown to amplify another gene 
that did not also amplify MYCN [36]. Several other amplifications have been also 
identified in NB cases and include amplification of DDXI gene at 2p24, MDM2 gene at 
12q13, the MYCL gene at 1p32 and unidentified DNA region from chromosome loci 2p22 
and 2p13 [37,38]. 
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2 Genetics of Neuroblastoma 
2.1 MYC Oncogenes and Oncoproteins 
The Myc proto-oncogene family is composed by three well-defined members, MYC, 
MYCN and L-MYC. From Bishop et al. pioneering work arose MYC discovery as the 
cellular homolog to the transforming gene v-myc of the avian MC29 myelocytomatosis 
transforming retrovirus [39,40]. 
On the heels of this revelation were the discoveries of other two genes paralog to MYC 
and related in gene structure and nucleotide sequence that were shown by cytogenetic 
analyses to be amplified in various human cancers. In 1983 MYCN was identified as an 
amplified gene found in NBs, while later small-cell lung cancers were found to carry 
amplified L-MYC [41,42]. Then, Schwab and colleagues point out the involvement of Myc 
oncogene family amplification in a variety of cancers, including retinoblastoma, small cell 
lung cancer cells, glioblastoma, medulloblastoma and astrocytoma [43,44]. 
Although a good degree of homology, Myc family members are characterized by a slightly 
different expression pattern that is tissue- and stage-specific: MYC is specifically 
expressed in proliferating tissues in the adult, whereas MYCN is present in many 
proliferating neonatal tissues and at highest levels in pre-B cells, forebrain, kidney, 
intestine and hindbrain. During gastrulation, MYCN levels are high in the embryonic 
mesoderm whereas MYC expression is mostly restricted to extraembryonic tissues. During 
differentiation, MYCN expression has been shown to persist in some tissues such as the 
retina, telencephalon, and intestine, where MYC is downregulated [45,46]. Both 
proliferative and differentiative compartments of the neural tube and brain expressed L-
MYC, together with the developing kidney, as well as the newborn lung [47,48]. 
Structurally, genes have a three-exon organization with long 5′ and 3′ untranslated regions 
(UTRs). Exon 2 and 3 contain the highly homologous major coding domain, whereas first 
exon is not conserved among family members but rather has regulatory functions [49]. 
They encode similarly sized nuclear phosphoproteins (∼50–55 kDa for MYC and MYCN 
while ∼40 kDa for L-MYC) which contain highly conserved clusters of amino acids that 
are likely to be important for nuclear targeting, nucleic acid binding and in vitro 
transforming activities [50]. Organization of Myc transcription factors is similar among 
paralogs and, to a lesser extent, its orthologs throughout evolution especially for certain 
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domains, whereas many of the sequence outside these well-defined domains are divergent 
among paralogs. In Figure 5, the functionally important conserved regions are 
diagrammed. 
 
Fig.5. Architecture of the MYC 
oncoprotein family. On the top, it is 
shown a generic representation of 
MYC protein. Below is a 
representation of conserved sequences 
present in the other family members. c-
MYC is drawn to scale at 439 amino 
acids while N- and L-MYC proteins 
are shown not in scale. They are respectively 464 and 364 amino acids in length, due to differences in the length of 
nonconserved sequences. MYC proteins possess: 1) a large unstructured amino-terminal region named TAD involved in 
transcriptional activation and containing the conserved region named MYC boxes MBI mainly involved in the regulation 
of MYC protein stability, and MBII that modulates the interaction with proteins such as GCN5, TRRAP, TIP48 and 
TIP60; 2) a middle segment rich in proline, glutamic acid, threonine and proline residues PEST as well as two conserved 
MYC boxes MBIII and MBIV and a nuclear localization sequence; 3) a C-terminal region with the basic helix-loop-helix 
leucine zipper bHLHz domain, necessary for the nucleic acid binding and for  interaction with MAX [51]. 
 
Compared to other oncoproteins such as SRC or RAS, MYC is unique because its coding 
region is rarely mutated. Instead, MYC’s oncogenic properties are unleashed by regulatory 
mutations leading to unconstrained high levels of expression [51]. 
2.1.1 MYCN Functional Activity as Activator and Repressor 
As for all proto-oncogenes, distinction must be drawn between their "normal" functions in 
untransformed cells and their "pathological" functions in tumor cells: even if the two are 
related, carcinogenic functions may represent only a subset of the physiological. MYC acts 
as a sensor integrating cellular signals and mediating transcriptional response that drives 
various cellular mechanisms. By activation (cyclin D1, D2, E, cdk4, cdc25a, id2, cul1, 
cks2) and repression (p15, p21, p27) of its target genes, MYC activates cyclin D1(D2, 
D3)/Cdk4(6) as well as cyclin E/Cdk2 and inactivates retinoblastoma protein RB driving 
cells through G1-phase and resulting in S-phase entry. Thus, the Myc protein family 
potently stimulates proliferation and inhibits differentiation [52]. Given the involvement of 
this transcription factors also in cell growth, immortality and genomic instability, in 
reducing cell adhesion and stimulating angiogenesis and metastasis, it is well established 
that deregulated proteins possess high transformation potential and are associated with 
poor prognosis in various types of tumors [53]. However, in the absence of sufficient 
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amounts of survival factors, MYC can induce apoptosis. This represents a security 
mechanism against hyperproliferative signaling and limits its proliferation-stimulating 
effect to situations where proliferation is appropriate [54]. 
The MYC family of proteins are an atypical family of transcription factors in that they can 
regulate approximately 10-15% of the whole genome [55]. As for the other members of the 
family, MYCN can exerts its functions as transcription factor only when associated with a 
small protein named MYC Interacting Protein X or MAX. As with all transcription factors, 
MYCN directly or indirectly recruits different sets of interacting proteins or cofactors to 
engage the basal transcriptional machinery. However, MYC–MAX interacts with a 
multiplicity of factors such as chromatin remodelers or antipausing factors, as well as other 
transcription factors such as MIZ-1 and the estrogen receptor. Thus, MYCN’s precise 
function in transcriptional activation and repression reflects the specific factors recruited, 
the chromatin context of the target gene and the presence of other transcription factors 
proximal to the binding site [53]. Furthermore, MYCN was shown to binds to histone 
modifiers and remodel domain of euchromatin that contain active gene highlighting a 
function that is independent from its activity as transcription factor and leading to 
hypothesized that MYCN can act as an enhancer and regulate genes at distance [56]. 
MYCN Canonical transactivation: The most relevant model of MYCN-mediated 
transcription activation postulates that MYCN increases local histone acetylation to keep 
chromatin in an active state in the promoter regions of target genes through interaction 
with TRRAP (TRansactivation/tRansformation Associated Protein). TRRAP acts as a 
scaffold for assembling multiprotein complexes to chromatin involving histone acetylation 
HAT complexes such as the SAGA complex SPT/ADA/GCN5/Acetyltransferase or the 
TRRAP-TIP60 complex, formed by TIP60 an H2A/H4 acetylase and the ATPase/helicase 
motif-containing cofactors TIP48/49 involved in chromatin remodeling that moves or 
displaces nucleosomes [57-59]. Factors such as positive transcription elongation factor b 
P-TEFb and TFII-H that stimulate transcriptional elongation through phosphorylation of 
Ser2 of RNA polymerase C-terminal domain, can also be recruited to the MYC/MAX 
dimer. Lastly, MYC has also a function in controlling RNA pol II promoter clearance 
through regulation of RNA pol II kinases expression via mRNA cap methylation, 
polysome loading and rate of translation [60]. 
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MYCN Repression: MYC-MAX heterodimers can also interact with other transcription 
factors and bind to Inr initiator element consensus to repress transcription. There are 
evidences that MYCN can directly be recruited to non-E-box promoter of target genes 
through association with other transcription factors, including SP1/SP3, MIZ-1, and NF-
YB/NF-YC. Myc-interacting zinc finger protein Miz-1 transactivates tumor suppressor 
genes as well as genes involved in cell cycle regulation through recruitment of the histone 
acetyltransferase p300. MYC interaction with Miz-1 and other transcription factors causes 
repression by recruiting HDACs to MYC-Miz complex and moreover through disruption 
of Miz-p300 interaction. Moreover, MYC-Miz complex inhibits MYC ubiquitination and 
subsequent degradation promoting MYC stabilization. [61] MYC is also involved in 
repression of target gene promoters via methylation, indeed MYC-MIZ-1 complex can also 
recruit the DNA methyltransferase DNMT3a. MYC represses many genes through 
induction of the tumor suppressor PTEN, which activates the histone-lysine N-
methyltransferase EZH2 via AKT phosphorylation inducing genome trimethylation of 
H3K27. Moreover, this is also the autoregolatory mechanisms used by MYC to limits its 
own expression [58,61]. Repression of genes that do not contain Inr sequences occurs 
through specific GC-rich regions recognized by MYC-formed complexes with factor such 
as the zinc-finger SP1 and subsequent recruitment of chromatin modifiers such as HDAC1 
[62]. 
 
 
 
 
 
Fig.6. Mechanisms of MYCN activation and repression of target gene transcription. A) MYCN-MAX transactivation 
occurs via E-box binding. Recruitment of histone acetyl transferases (HATs) including p300/CBP, GCN5- and Tip60-
containing TRRAP complexes result in an open chromatin state, and MYCN-promoted phosphorylation of the C-terminal 
domain of RNA polymerase II. B) Repression mediated by MYCN of Miz-1/Sp-1 induced transcription. MYCN-MAX 
dimer recruits various factors including DNA methylase 3a (Dnmt3a) and histone deacetylases (HDACs) that induce a 
repressed chromatin state [62]. 
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2.1.2 Regulating MYCN Expression 
The involvement of the Myc protein family in so many cellular mechanisms necessitates to 
finely control its expression and protein fate at almost every level known to molecular 
biology: transcription initiation and elongation, translation, stability of mRNA and protein 
and furthermore, protein activity is regulated by posttranslational modifications and 
interacting proteins [55]. Regulation occurs also through short half-lives (∼30 minutes) of 
MYC mRNA transcripts and proteins and through their fine expression as cells enter the 
cell cycle. Indeed, MYCN has a strictly spatial and temporal expression related to 
embryonal development of the peripheral nervous system [4]. Neural crest-related 
precursor cells are multipotential and migrating cells that give rise to the enteric nervous 
system, the peripheral nervous system, pigment cells, Schwann cells and cells of the 
adrenal medulla and craniofacial skeleton. MYCN expression is high when these migrating 
cells are in highly proliferative state, while MYCN expression decreases when cells 
undergo differentiation. Any dysregulation of MYCN expression impairs the ability of 
progenitor cells to undergo differentiation [45]. Furthermore, tissue specific expression of 
MYCN is due to the presence of TSE sequence (tissue-specific element) within the first 
intron that acts at posttranscriptional level [63]. 
Regulation of MYCN protein level: Several proteins have been described that alter the 
stability of MYCN mRNA and its translation efficiency [64]. Interestingly, some of the 
well characterized proteins mediating MYCN mRNA stability binds to AU-reach elements 
ARE at 3’UTR, some of them with a positive action such as Mdm2, Hud and Wig-1, and 
others with a negative action on MYCN stability, i.e. TAp73. Furthermore, MYCN seems 
to auto-regulate itself through modulation of target genes encoding for proteins involved in 
its stability. Indeed, Mdm2 is a direct positive target of MYCN, while MYCN can repress 
transcription of TAp43 [65-68]. 
Several studies identified individual miRNAs targeting 3’UTR of MYCN as involved in 
negative regulation of its stability or translation (e.g. miR-30e, miR-29a/b/c, miR-34a, 
miR-19a/b, miR-101, miR-181a, miR-202, miR-449a/b and let-7c/e). The best 
characterized MYCN-targeting miRNA is miR-34a located at ch.1p36, a frequently deleted 
region in MYCN-amplified NBs.  Overexpression of mir-34a in MYCN-amplified NB cell 
lines, as well as let-7 and miR-202, inhibits MYCN mRNA translation [25,69]. However, 
miRNAs-MYCN interactions are mutual, as MYCN itself targets miRNAs. 
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Indeed Speleman et al. demonstrate that MYCN-targeting miRNAs are downregulated 
during MYCN-driven tumor formation [70]. 
Another level of MYCN protein regulation is interdependent posttranslational 
modifications, that affect the activity, stability and degradation of MYCN. As for other 
MYC family members, MYCN is phosphorylated at multiple sites located over the entire 
protein. Luscher et al. identified a region that lies within a PEST sequence involved in 
MYCN degradation as substrate of kinase CK2, an enzyme which shows enhanced 
expression in many tumors [71-73]. Also the dimerization partner of MYC, MAX is a CK2 
substrate and phosphorylation of MAX results in change in DNA binding properties of 
MYC/MAX complexes. Together these findings suggest a role of CK2 in stabilizing MYC 
protein and in regulate DNA binding properties [74].  
A further phosphorylation area located within the TAD of MYCN, involves Thr-58 and 
Ser-62 amino acid residues whose phosphorylation is tightly interdependent. In response to 
activation of the MAPK signaling, Cdk1 phosphorylates Ser-62 providing a priming for 
GSK3β binding, a second kinase which subsequently phosphorylates Thr-58. 
Dephosphorylation of Ser-62 through PP2A protein phosphatase 2A sensitizes MYC 
proteins to bind the tumor suppressors Fbxw7 or Huwe1 and recruit a ubiquitination 
complex to MYCN protein. Aurora A kinase has been recently identified as overexpressed 
at both mRNA and protein level in primary MYCN amplified NBs and its high expression 
levels correlates with a high-risk group and poor prognosis. It has been shown that AurKA 
inhibit degradation of ubiquitinated MYCN via inhibition of Fbxw7 pathway [75,76]. 
Another post-translational modification to which MYC is subject is lysine acetylation. 
Indeed, it has been established that stimulation of acetylation decreases ubiquitination of 
MYC and enhances its stability, given also that some of the identified acetylation sites 
overlap with the ubiquitination sites [75]. In absence of growth factor-dependent signals, 
proteosomal degradation of MYCN allows cells to exit the cell cycle and undergo 
differentiation [76]. 
Transcriptional control of MYCN: First, MYCN gene expression is regulated at 
transcriptional level. MYCN promoter region has been shown to have consensus for 
transcription factors that positively (e.g. Shh, E2F, Sp1-3) or negatively (e.g. ROR) 
regulates its expression in response to different mitogenic signals [64]. 
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During the last years, it was shown that MYCN is an essential downstream effector of 
Sonic hedgehog (Shh) signaling pathway and this transcriptional activation is required for 
both normal and neoplastic proliferation of neuronal precursors in the cerebellum. 
Importantly, mouse model with constitutively activated Shh signaling results in 
medulloblastoma formation but no evidence of hyperproliferation or tumor formation was 
detected in mice nullizygous for MYCN [77]. MYCN is also a pivotal target for Wnt 
signaling in promoting proliferation and differentiation of neocortical neurons via β-
catenin/Tcf3 transcription complex pathway [78].  
Regulatory sequences are also located outside the promoter region: the previously 
mentioned TSE located within intron 1 lies near a consensus binding site for RORa1 and 
RVR designated as RORE (ROR response element). Negative regulation of ROR was 
demonstrated through mutation of RORE sequence and subsequent increase of the 
oncogenic potential of MYCN gene in rat embryonic fibroblast [79]. The multiple signal 
transduction cascade that target MYCN promoter are often deregulated in cancer cells and 
contribute to enhanced its expression but amplification of MYCN in the form of DMs or 
HSRs and the resulting overexpression seems to be of greater impact for the malignancy of 
the NBs [75,11].  
Strieder et al. identified three transcription factors involved in MYCN expression in 
MYCN amplified NB cells. His work demonstrates the binding of E2F-1, 2 and 3 to the 
proximal MYCN promoter in vivo and that inhibition of E2F activity in through 
overexpression of p16INK4A induced a reduction MYCN expression. There is also lines of 
evidence that E2F proteins are involved in the negative regulation of MYCN by TGF-β and 
retinoic acid. These data underline the role of E2F transcription factors in both MYCN 
activation and repression in neuroblastoma [80]. E2F/Rb pathway is essential for 
modulation of cell cycle, differentiation and survival of various cell types in the 
developing and adult CNS and, although neither RB gene mutations nor any other protein 
mutations known to inactivate the pRb pathway in other types of tumor have been detected 
in NBs, recent evidence suggests that E2F/Rb activity in NBs may be deregulated [81]. 
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2.2 The E2F/Rb Pathway in Disease Development 
Proper development of CNS requires coordination between proliferation, differentiation 
and survival input signals from the environment that activate transduction pathways and 
converge on the E2F/Rb molecular switch [82]. One of the hallmarks of cancer cells is 
their insensitivity to antiproliferative signals, such as antigrowth factors. From novel 
studies, the central role of retinoblastoma protein RB and its relatives p107 and p130 have 
emerged, in mediating these antiproliferative signals. Indeed, pRb pathway is found 
deregulated in a large number human cancers. This pathway involves also the negative 
regulators of cell proliferation INK4 family cyclin-dependent kinase inhibitors, and the 
positively acting Cyclin D/CDK4-CDK-6. The downstream effectors in the pathway are 
the E2F transcription factors [83]. 
2.2.1 RB Proteins  
RB1 was the first identified tumor suppressor gene whose sequential loss or inactivation of 
both alleles was claimed to be responsible for the retinoblastoma. Gene encodes for pRB, a 
member of the pocket protein family RB together with its relatives p107 and p130 encoded 
respectively by RBL1 and RBL2 genes. The central core of RB-family proteins is the 
'small pocket' domain defined as the minimal domain necessary to bind to viral 
oncoproteins such as simian virus TAg through their peptide LXCXE motif, essential for 
stable interaction and present in many chromatin regulating proteins with which RB 
proteins interact [84]. (Fig. 6) 
Fig.7. Architecture of the RB protein family. The main 
homology sequence lies in the well-conserved small 
pocket region, which consists of A and B domains (green) that 
represent a single cyclin fold domain together with a flexible 
interdomain linkers. The 'large pocket' is the minimal growth 
suppressing domain of RB-family proteins and it is capable of 
binding E2F transcription factors as well as viral proteins. p130 
and p107 have also insertion subject to regulatory 
phosphorylation to maintain protein stability and a CDKs interacting regions.  Revisited from [84]. 
 
The large pocket (C-terminal domain and small pocket) is sufficient to interact with E2F 
family of transcription factors to control proliferation, apoptosis, differentiation and 
development. RB but not its relatives, has a docking site used only by E2F1, and a short 
peptide region in the C-terminus that is competitively occupied by cyclin/cyclin dependent 
kinases (CDKs) or protein phosphatase 1 (PP1) [84]. 
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2.2.2 E2F Proteins  
E2F transcription factor family positively (E2F-1 to E2F-3) and negatively (E2F-3b to 
E2F-8) regulates expression of genes involved in cell cycle regulation and synthesis of 
DNA through binding to the canonical consensus TTTCCCGC and its slight variations in 
the promoter of target genes [85].  
 
 Fig.8. Domain structure of E2F family and their Rb 
family-binding partners. All E2F proteins have a DNA-
binding domain (DB pink), and most of them also have a 
dimerization domain (DIM blue) which allows interactions 
with an obligate dimerization partner (DP). The Rb family-
binding domain (green) located in the C-terminal region of 
the activators E2F1–E2F3 is responsible for binding 
retinoblastoma protein (Rb), whereas p107 and p130 bind 
to a similar domain on the repressors E2F4 and E2F5. 
E2F6 and E2F7 do not bind pocket proteins, but E2F6 
binds to the Polycomb group of proteins (PcG). Thus, repressor E2Fs form two subgroups; E2F3b-E2F5, which bind RBs 
to form a functional repressive complex, and E2F6-E2F8, which act independently of Rb binding. The E2F1–E2F3 
isoforms have a Cyclin A domain (CycA yellow) and a nuclear localization signal (NLS), whereas E2F4 and E2F5 have 
two nuclear export signals (NESs). Revisited from [85]. 
De Gregori et al. point out the overlapping functions of the E2Fs among the members of 
activators and repressors in the cell cycle control, but also unique functions during tissue 
homeostasis, development and tumor formation. Loss of all three activator E2Fs and/or 
overexpression of E2Fs 4 and 5 results in cell cycle arrest but mutant mouse models 
provide evidence for E2F-1 specific role also in apoptosis [86]. 
The regulatory essence of E2F complexes is based on the ability to interact with pocket 
proteins but also to bind DNA with high affinity, moreover, classical E2Fs (E2F1-E2F6) 
need to form heterodimers with DP proteins. Hypophosphorylated pocket proteins can bind 
E2F sequestering their transactivation domain and recruiting chromatin modifiers but in 
contrast, hyperphophorylated RB are unable to interact with thereby liberating their 
transactivation domain and allowing transcription of E2F target genes. Association of Rb 
to activator E2Fs masks their transactivation domain responsible for transcription of target 
genes and furthermore induces recruitment of chromatin remodeling complexes (e.g. 
HDAC); whereas binding of RB proteins to repressor E2Fs (E2F4-5) mediates recruitment 
of repression complexes to repress transcription [81,87]. 
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2.2.3 Overview on E2F/RB Pathway and Cancer 
Main hallmark of cancer cells is insensitivity to antiproliferative stimuli and during the last 
decade there has been a growing interest for the central role of RB proteins in mediating 
these antiproliferative signals for various reasons. Firstly, RB pathway is found 
deregulated in a large number human cancers and pathology. Alzheimer, Parkinson’s 
disease and Amyotrophic lateral sclerosis show active E2F and aberrant or 
hyperphosphorylated Rb expression resulting in increased expression of E2F target genes, 
thus leading to the notion that neurodegeneration could be consequent to activation of 
apoptosis after abortive cell-cycle re-entry [88-90]. Indeed, the previously mentioned role 
of E2F1 in apoptosis was also confirmed in cortical neurons: its depletion conferred 
protection to cerebellar granular neurons from dopamine-induced cell death and to cortical 
neurons from b-amyloid induced death [81,91]. 
Moreover, this pathway involves the main regulator of cell proliferation [83]. 
Involvement in Cell cycle: E2F/RB pathway is a master cell cycle regulator, and the 
impairment of the pathway appears to be a necessary step in human oncogenesis. 
Phosphorylation of RB family proteins is sequentially mediated by different cyclin-CDK 
complexes in a temporal specific manner. In response to mitogens, cyclin D expression is 
upregulated and it forms complexes with CDK4 or CDK6 and phosphorylates Rb proteins 
preventing RB from binding to E2Fs. Thus, activator E2Fs, whose expression is maximum 
during S phase transition, are able to induce transcription when free from RB. On the other 
hand, repressor E2Fs are expressed all through the cell cycle, especially since their typical 
expression in quiescent cells, and play main roles in transcriptional repression in G0/G1 
bound by Rb proteins [83]. The fine balance between repressor and activator E2Fs regulate 
cell cycle progression [92,93]. Disruption of the RB pathway induces cell cycle arrest 
through upregulation of CDK inhibitor p21Cip1 or p27Kip1 or if cells fail inducing cell cycle 
arrest, cells undergo apoptosis via activation of p53 pathway or induction of TAp73, a p53 
family member, which activates various pro-apoptotic genes [87]. 
Evidence of the role of activator and repressor E2Fs in proliferation come from knockout 
or deregulation study: loss of all three activating E2Fs and/or overexpression of E2Fs 4 
and 5 results in cell cycle arrest. Moreover, ectopic expression of activators E2Fs in 
quiescent immortalized rodent fibroblasts is sufficient to drive them into S phase. Mutant 
mouse models provide evidence of E2F1 specific role also in apoptosis and in proliferation 
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of progenitors of the central nervous system; knockdown of E2F3 points out its role in the 
proliferation of adult neural precursor. [84,85]. 
Effect of RB mutations in mouse models are indicated to be embryonic lethal and RB null 
mice shown increased apoptosis in the CNS especially in spinal cord, spinal ganglia and 
hindbrain.  
Interestingly, despite RB expression in both intermediate and ventricular zone of the neural 
tube during development, the apoptotic cells distribution in the Rb−/− mice were confined to 
the intermediate zone, containing progenitors committed to the neuronal lineage suggesting 
a role for RB in the proliferation of adult neural precursor [94-96]. 
 
Fig.9. Examples of the known mechanisms of transcriptional 
regulation with which E2Fs coordinate cell-cycle progression, 
survival, cell fate, and proper cell development. A) acetyltransferase 
p300 is recruited by E2F1 to chromatin to promote the expression of 
cell-cycle related genes. B) An example of E2F-mediated repression 
during neuronal development: repressor E2F is necessary for the p107 
recruitment to the Notch1 promoter. C) E2F4 is involved in adult 
neuronal survival by recruiting a complex formed by p130, HDAC1, 
and the methyltransferase Suv39H1 to the promoter of the 
proapoptotic gene B-Myb. Revisited from [81] 
 
 
 
In the E2F/RB-mediated onset of pathology there could be distinct transcriptional 
mechanisms mediated by deregulated E2F or physiologically activated E2F. Although the 
released from RB protein, physiologically activated and deregulated E2F are functionally 
different: the first one activates only typical E2F targets, whereas deregulated E2F induced 
transcription of both typical and atypical E2F targets. This is due to the temporarily release 
from RB of physiologically activated E2F that is predicted, however, to be ‘under control’ 
of RB. On the other hand, deregulated E2F is totally out of RB control because of 
dysfunction on the related pathway. Atypical E2F target genes include the first identified 
ARF gene, the major activator of p53 pathways, the CDK inhibitor p27Kip1 and the tumor 
suppressor Tap73 [87]. 
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2.2.3 E2F/RB Pathway and Neuroblastoma 
During past years, efforts have been made to clarify the genetic programmes at the base of 
generation of cell diversity in the nervous system. Recent finding points out that the 
diversity in the nervous system is due to extensive interactions and synergies between 
transcription factors of the homodomain HD and bHLHz families. Indeed, HD proteins 
such as Pax6 and Otx2 were shown to pattern to the neural primordium and the expression 
in mice of proneural bHLHz proteins such as Mash1, Math1 and Ngn1-3 were shown to 
induce generation of differentiated neurons [97]. Cooperation between proneural and 
inhibitory bHLHz and HD proteins was further demonstrated by Sugimori and colleagues’ 
work, underlining a molecular code that results in cell cycle exit and differentiation and 
thus in spatial and temporal patterns of neurogenesis and gliogenesis [98]. 
During embryogenesis, RB proteins control proliferation and activation of a neurogenic 
gene expression program of specific populations of neuroblasts. Various neurogenic 
transcription factors are involved in neuroblasts differentiation and their transcriptional 
activity is finely controlled by ID (inhibitor of DNA binding) protein family through a 
sequestration mechanism. 
ID protein family comprises four conserved transcriptional regulators firstly recognized for 
their ability to repress bHLHz protein activities and then also activities of ETS, paired box 
PAX and RB proteins. ID proteins have a role in the timing control of stem cell 
differentiation and cell fate during normal development [99]. 
Because the ID proteins are known to sequester RB, it is convincing that the amount of RB 
levels during early development could be crucial for the appropriate activation of the 
commitment program. Although the deeper understanding of ID functions in cancers 
maintenance and progression, the transforming role of ID proteins is postulated on the 
basis of their capacity to inhibit the massive and multimodal tumor-suppressive RB 
pathways through direct binding ID2/ID4-RB or indirectly through the blocking of ETS-
mediated expression of INK4A by ID1 [100]. 
ID overexpression was also proposed as prognostic indicators in Neuroblastoma and not 
surprisingly, NB cell lines carrying MYCN amplification, usually overexpress ID2 to 
constitutively bypass the cell cycle checkpoint imposed by RB, providing another missing 
piece of the puzzle for determining the onset of NBs [101]. Although to date, we still lack 
a comprehensive picture of the downstream molecular events that are controlled by the 
reciprocal regulation of RB and ID proteins, evidences suggest a role for aberrant 
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modulation or impairment of ID/RB/E2F regulatory pathway during embryogenesis 
resulting in the formation of NB [99,101]. 
2.3 MYCN/MAX/MXD Network  
Within two years of MYCN’s discovery in NBs, amplification of MYCN was shown to 
correlate with poor prognosis in patients, a biomarker that is still used today to stratify risk. 
MYCN transcription factor belongs to an extended network defined by the presence of a 
basic helix-loop-helix leucine zipper (bHLHz) motif that is known to mediate protein-
protein interactions among members of the network and DNA binding. Indeed, MYC is 
known to heterodimerize with MAX at consensus Enhancer-box (E-box) sequences located 
into or in the immediate proximity of promoters or enhancers of the regulated genes to 
activate transcription. Both canonical (CACGTG) or not (CANNTG) E-boxes are the 
sequence recognized by all the MYCN/MAX/MXD network proteins which MYCN 
belongs to [51]. 
2.3.1 Main members of the Network 
Myc Interacting Factor X, MAX: MYC family functions are mediated by MAX, a stable 
bHLHz protein that, in contrast with MYC family members, is expressed in both resting 
and proliferating cells, regardless of MYC levels. [54] The heterodimer “signature” 
comprises groups of target genes involved in pluripotency and growth, but also proteins 
with a role in the normal development of sympathoadrenal lineage cells, such as the 
multidrug resistance protein 1 (MRP1), α-prothymosin, MASH1, Id2, telomerase, MCM7, 
Pax-3, leukemia inhibitory factor, activin A and MDM2. [50] [12] As previously 
mentioned, MYCN-mediated transcriptional activation occurs through interaction with 
MAX and subsequent recruitment of TRRAP complexes. 
MAX network transcriptional repressor MNT and Max Interacting Proteins, MXD: From 
the presence of MAX in cell lines with no MYC expression and from its weakly 
homodimerization capability, arises the evidence that MAX can form heterodimers with 
other related proteins of the network, known as MXD1-4 and the more distantly related 
MNT. These proteins, that compose the MAD protein family readily heterodimerize with 
MAX and bind DNA at the same E-box sequence as MYCN, but function as 
transcriptional repressor acting as MYCN main antagonists [102]. The capability of 
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MXD1-4 and MNT proteins to act as transcriptional repressor, further strengthen the 
model in which MXD proteins antagonize MYC in regulating many aspects of cell biology 
[103]. In contrast to MYC, proteins of the MXD family possess an mSin3 interaction 
domain SID (Fig.8) that has a critical role in ensuring MXD/MNT functions. While MXD 
with an impaired SID has little biological activity, MNTDSID gain transforming activity 
suggesting other relevant MNT functions [104].  
MGA: the bHLHz MAX protein binds also MGA. It differs from other members of the 
network which in general are rather small molecules and secondly, because it has 
additional functional domains that allow it to act both as an activator or repressor. Indeed, 
MGA has two distinct DNA binding domains, a T domain and bHLHz DNA-binding 
motifs, suggesting it can interact with DNA not only at E-boxes level but also through 
sequences recognized by its T-box DNA binding motif. MGA is known to take part to a 
repressive complex that binds MYC and E2F target genes [104]. 
MondoA, ChREBP and Max like Protein, MLX: the bHLHz MAX like protein MLX 
heterodimerizes also with ChREBP/MondoB and MondoA as well as with a part of MXD 
family proteins. While MYC, MAX and MXD proteins localize exclusively in the nucleus, 
MLX and MONDO proteins have mainly cytoplasm localization but, in response to 
metabolic stimuli, can shuttle between the two compartments. MXD–MLX dimers can 
bind both non canonical or canonical E-box sequences, and repress transcription, acting 
similarly to MXD–MAX heterodimers [105,106]. Target genes of MondoA/ChREBP-
MLX dimers are involved in glutamine and glucose metabolism that are essential for cells 
both in physiological and pathological conditions [54]. 
 
 
 
 
Fig.7. Diagram of the MYCN/MAX/MXD 
network. All members are represented and two-
headed arrows underline their interactions. Green 
arrows indicate transcriptional activation whereas 
red lines, repression functions. E-Box, Enhancer-
box; ChoRE, Carbohydrate response element. 
[102] 
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Diagrammed in Figure 7 the representation of the enlarged network through which Mondo, 
MXD and MYC gene families mediate a wide transcriptional response to growth arrest, 
mitogenic and metabolic signals. Structural differences between the network members 
directly reflect the deep functional activities of these proteins (Figure 8).  
 
 
Fig.8. Representation of the main 
domains of the members of the 
network (representative member of 
each subfamily is depicted).  
BHLH, Basic helix loop helix; LZ, 
leucine zipper; MBI-IV, MYC box 
domains; TAD, transcriptional 
activation domain; DCD, 
dimerization and cytoplasmic 
localization domain; NLS, nuclear localization signal; SID, SID3-interacting domain; TRD, transcriptional repression 
domain. The Glucose sensing domain is composed by six conserved regions named MONDO Conserved Region (MCR). 
Revisited from [102]. 
Given the intricate organization of the network, it is justifiable to consider that imbalance 
in the expression profile of the network members may have a significant biological impact 
by changing the complex physiological interactions between the members themselves. This 
notion is based first, on the consideration that MYC, MXD, or MONDO family proteins 
compete for binding to MAX or MLX limiting their free quantity required for other 
connections. A second consideration is that the same e-box could be target of both 
transcriptional activation and repression induced by different heterodimers imposing 
various consequences in terms of gene target expression [106]. 
2.3.2 MAX role in the balance of MYCN activities 
To further investigate MYCN functions as activator and repressor, it is also necessary to 
understand the importance of MAX in preserving the equilibrium among activated and 
repressed transcription of MYCN target genes. Evidence for MAX germline loss-of-
function mutations in patients suffering from pheochromocytoma has highlighted the role 
of MAX as tumor suppressor gene. All mutations are located within the bHLHz domain, 
necessary for the stability and specificity of dimer formation and for DNA recognition and 
the major part of these affected the casein kinase II phosphorylation sites involved in 
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MAX-mediated DNA binding [51,107,108]. Further evidence for the role of MAX in 
balancing MYCN target genes comes from the reintroduction of MAX in PC12 cells that 
induces transcriptional repression and a decrease in growth rate. PC12 is a 
pheochromocytoma cell line derived from the rat adrenal medulla that does not express 
MAX protein. Additional experiments on the same cell line highlights MYC independent 
function as a transcriptional regulator despite the lack of MAX interactor. Therefore, 
MYC-MAX complexes may not be the only condition for MYC-dependent gene 
expression. As result of MAX mutations, it is an imbalance in the network that is also 
responsible for pheochromocytomas and this could also be due to increased MLX 
recruitment [109]. All these findings confirm the role of imbalance of the 
MYC/MAX/MXD axis in the growth of aggressive neural tumors, and argue that the 
genetic hallmark of malign neuroblastoma, i.e. MYCN amplification could lead to an 
active MAX-indipendent MYCN function. 
 Interestingly, degree of NBs aggressiveness depends directly on the MYCN copy number, 
therefore ablation of MAX-MNT or MAX-MYC dimers in pheochromocytoma could 
contribute to the same oncogenic MYC deregulation that occurs in NB [5,109]. 
Although MYC independent activities, it has been supposed that MAX may also be 
required for the correct folding of MYC [110]. Moreover, MAX is the only member of the 
network that homodimerizes both in vitro and in vivo, even though MAX homodimers are 
less stable than MYC-MAX heterodimers or other heterodimers of the Myc network [111]. 
Because MAX lacks a transactivation domain, MAX homodimers fail to regulate 
transcription, but it was demonstrated that, while MYC overexpression activates, MAX 
over-expression has been reported to repress the transcription of genes bearing c-MYC 
binding sites. Furthermore, MAX-mediated repression is relieved by overexpression of c-
MYC [112]. 
Recent studies suggest that the amount of MAX is limited and MYC and MNT really 
compete for binding to. To date, there is no further information on the different binding 
capacity of MYC or MXD proteins [113, 114]. 
Alternate mRNA splicing produces two major highly conserved MAX isoforms, the longer 
of which MAXL differs from the shorter form MAXS for a 9-amino acid insert. Both 
proteins are expressed at approximately equal levels in most cell types and, unlike MYC, 
are highly stable and unresponsive to the proliferative state of the cell.  In vitro shift assay 
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demonstrated that MAXL can bind DNA more strongly than MAXS and in vivo analysis 
on rat fibroblast pointed out that MAXL is able to repress a MYC-responsive reporter gene 
whereas MAXS had little effect on its expression.  In comparison to MAX(S)-
overexpressing cells, ones overexpressing MAXL showed reduced expression of 
exogenous or endogenous MYC responsive genes, grew more slowly, showed accelerated 
apoptosis after growth factor depletion. These differential effects of two MAX isoform can 
at least be explained partially by the differences in their DNA binding abilities and their 
effects on target gene expression [115]. 
2.3.3 Evidence for MNT as a MYCN antagonist  
Because of its chromosomal location (ch.17p) frequently deleted in cancer, MNT is the 
mainly studied transcriptional factor of the network and, it is ubiquitously expressed as 
MAX, with no fluctuations among cell cycle [108]. The conventional model in which 
MNT and MXD proteins act as MYCN antagonists, has been supported by studies 
demonstrating that overexpression of these factors led to growth arrest and suppressed 
MYC/RAS induced transformation of fibroblasts. Furthermore, conditional MNT deletions 
in T cells or in mammary epithelium of mice display hyperproliferation and bring to 
development of respectively T-cell lymphomas and mammary adenocarcinomas [116]. 
Moreover, murine embryonic fibroblasts (MEFs) derived from these mice, exhibit many of 
the hallmark characteristics (i.e. low growth rate, prone to apoptosis, efficiently avoid 
senescence) of cells subjected to forced MYC expression suggesting that an analogous 
mechanism of tumorigenesis is operating [117].  
In addition, MYCN and MNT are known to target the same genes. Evidences for MNT 
antagonisms of MYC also come from murine lymphoid cells. In primary T cells, MYC is 
required for the proliferation and growth of immature thymocytes but its growth can be 
inhibited by ectopic expression of MXD proteins [54]. Furthermore, MNT deficient cells 
like cells that overexpress MYC, have increased proliferation and sensitivity to conditions 
that induce apoptosis [118]. 
Functional antagonisms between MYC and MNT/MXD: While MYC proteins act as 
transcriptional activator through their TAD domain, MXD or MNT–MAX heterodimers 
result in transcriptional repression through their SIN3 interaction domain (SID) with which 
can bind one of four paired amphipathic α-helical (PAH2) motifs within the large 
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corepressor complex known as mSIN3 and exerts its main function as repressor through 
HDAC1- and 2-mediated histone deacetylation [116]. Thus, a second level of biological 
antagonism, in addition to competition for MAX and DNA binding, occurs via histone 
acetylation and deacetylation. As for MNT-MAX heterodimers, also MNT-MLX repress 
transcription through interaction with mSIN3 recruitment of HDACs [4]. 
 Another level of MYC/MXD competition is histone methylation. MXD recruit histone 
demethylase inducing H3K4me3 demethylation at the TERT promoter thus inducing 
decreased expression of TERT in human promyelocytic leukemia cells HL-60 during 
DMSO-induced differentiation [119,120].  Taken together, these data lead to hypothesize 
that the MXD proteins can antagonize MYC function through inhibition and promotion of 
both histone acetylation and methylation. However, further binding analysis of MYC and 
MXD family proteins will be required to fully understand the functional relationships 
among network factors [54]. 
2.3.4 Role of the Network in cancer 
Expression and function of network members, which both collaborate or antagonize with 
MYC, can affect biological outcome of MYC-deregulated tumor.  Altered expression of 
MYC is necessary to establishment and maintenance of many tumor and it was proposed 
that MXD family members could antagonize MYC function acting as tumor suppressors. 
Schreiber et al. first proposed MXD2 as tumor suppressor gene as its constitutive deletion 
in mice resulted in a tumor-prone phenotype and hyperplasia but to date, there is no further 
evidence supporting the idea of MXD family as tumor suppressors [121]. Suppression of 
MXD1 in mice results in a mild phenotype with just slight maturation impairment of 
granulocyte progenitors [122]. Mice lacking MXD2 displayed a hyperplastic phenotype in 
multiple tissues while suppression of MXD3 seems to sharpen sensitivity to apoptotic 
stimuli. The bland phenotypes of the single-gene MXD1–4 knockouts could be due to 
redundancy among paralogs or, moreover to their irrelevant expression in the context of 
MYC-driven oncogenesis given their limited expression at arrest and differentiation time 
points [123]. 
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This may not be the case for MGA and MNT, which appear to act as tumor suppressors 
[54].  
Loss-of-function mutations in MGA have been identified in chronic lymphocytic leukemia 
and recent studies on MNT deletion show that it acts as antagonist but also allowing 
MYC’s oncogenic activities through balancing MYC induced apoptosis or proliferation 
[124,125]. 
It’s interesting to highlight that the lethal effect of combined MNT loss and MYC 
overexpression in T cells prevents the formation of highly penetrant thymomas that form in 
MNT replete T cells overexpressing MYC. In the same cell lines, but also in MEFs, MNT 
deficiency and MYC overexpression is coupled with high levels of mitochondria-generated 
superoxide/ROS that, when accumulated beyond thresholds could be toxic and induce 
apoptosis. Moreover, these cells exhibit low oxygen consumption, thus leading to 
hypothesize that defective oxidative phosphorylation may contribute to excessive ROS 
production. Less is still known about loss of MNT in high MYC context but the existing 
data underline the role for MNT in supporting the hypermetabolic state induced by 
mitogens and high MYC activity [117]. 
It is important to note that MXD/MNT proteins maintain their repressive activity also 
when bound to MLX thus, the phenotypes resulting from altered expression of MXD/MNT 
may be due to by heterodimerization with MLX. While MXD-MLX dimers mediate 
repression function, MONDO-MLX represent the positive transcriptional arm of the 
network which control the lipidic and glucidic cellular metabolism. Although MONDO-
MLX pathway has not been well investigated, there is evidence that silencing of 
MONDOA in NB cells induces apoptosis underlining a cooperation between MONDOA 
and MYC in inducing tumorigenesis [126]. 
It is well known the MYC capability to negatively autoregulate its own expression through 
the involvement of the Polycomb complex, usually found impaired in cancers. Due to the 
findings that Miz-MYC complex repress MXD4 in erythroleukemia cells, and following 
the discovery of MYC-mediated upregulation of Mondo proteins, it is possible to extend 
the regulatory cross talk among all network members [127-129]. 
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Differentiation: Grade of differentiation is used as a measure of cancer progression and 
aggressive MYCN-amplified NBs cells are characterized by a low grade of differentiation.  
MYCN acts as regulator of a set of genes involved both directly and indirectly in neuronal 
differentiation processes [8]. 
In NBs context, the Trk family of neurotrophin signaling receptors are strongly correlated 
to the biological and clinical features such as differentiation grade of NB tumors. Trk 
receptors have critical role in the development and maintenance of the central and 
peripheral nervous systems and their expression is differential and stage disease specific 
(see par.1.3). MYC regulation of TRK expression was investigated and it was pointed out 
that NGFR expression is repressed through binding of MYCN to the NGFR promoter. 
Furthermore, siRNA against MYCN in NB cells, could re-induce NGFR expression and 
sensitize neuroblastoma cells to NGF-mediated apoptosis [30,31]. 
During the progression of the differentiation process, MXD1–MAX complexes displaced 
MYC–MAX heterodimers resulting in repression of MYC target genes. The involvement 
of the MYC/MAX/MXD network results evident also from the temporal tight regulation of 
member expression: while MNT and MAX appear to be expressed independently from cell 
cycle, MXD expression is confined to differentiated cells. [125]. On the other hand, minor 
effects in mice with MXD depletion has led to the idea that MXD proteins may not directly 
offset MYC activity but somehow they act together with other differentiation factors to 
repress proliferation and growth genes induced by MYC before differentiation [54]. 
Proliferation: Tumorigenesis is the result of cell cycle disorganization and thus, 
uncontrolled cellular proliferation. These events involved conservatory molecules such as 
cell cycle genes and their products: cyclins, cyclin dependent kinases (Cdks), Cdk 
inhibitors (CKI) and extra cellular factors (i.e. growth factors). MYC is known to be 
associated with proliferation, whereas MXD proteins expression is linked to non-
proliferating cells. MXD3 and MNT are exceptions to this inverse MXD expression 
pattern: MXD3 expression is restricted to cells in S phase, whereas MNT is present 
regardless of cell cycle and differentiation [118,122]. 
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Fig.8. Representation of the control of promoter activity by MYC/MAX/MXD network members during proliferation or 
differentiation and proposed mechanisms. Upper panel: MYC binds to SWI/SNF complex involved in nucleosome 
remodeling; interacts with TRRAP complexes necessary for change in the acetylation status of core histones. Other 
components are involved including TFs and subunits of the PolII complex. Middle panel: MAX has not been reported to 
bind TFs and dimers do not influence directly promoter activity but compete for DNA binding. Lower panel: mSin3-
dependent repressor complex is recruited through MXD proteins and induce deacetylation of core histones and increased 
chromatin compaction. E box: refers to a DNA element that is recognized by MYC/MAX/MXD network members; RE: 
response element for transcriptional regulators; Ac: acetylation of histones; TF: transcription factor; HAT: histone acetyl 
transferase; HDAC; histone deacetylase; revisited from [104] 
In the context of the neuroblastoma, MYCN is able to affect the balance between 
proliferation and differentiation by promoting transcriptional activation of several genes 
involved in cell proliferation. When ectopically induced, it stimulates the re-entry of 
quiescent cells into cell cycle and shortens the progression through the cell cycle, 
specifically reducing the G1 phase and decreasing cell attachment to the extracellular 
matrix. Nevertheless, reduction of MYCN expression level, using MYCN anti-sense, 
promotes cell cycle arrest, differentiation, and apoptosis [62]. 
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3 Current treatment strategies for Neuroblastoma  
To date, current treatment for NB consists of surgery, chemotherapy, radiation, and 
biotherapy but the main treatment for NB is based on chemotherapy, which reduces the 
size of primary tumor facilitating surgery and eradicates distant metastasis. Surgical 
intervention is recommended in all cases in which tumor location permits; local 
radiotherapy is helpful in completing therapy. High dose chemotherapy is based on the 
combined use of cytotoxic drugs belonging to different molecular class types, however 
these treatments could lead to possible selection of a drug-resistant cellular clones and 
moreover, delivery of non-specific cytotoxic drugs leads to high incidence of side effects 
due to high grade of non-specificity, meaning a significant obstacle for NB treatment.  
To date, main drugs targeting MYCN that passed the pre-clinical trial belong to iron 
chelator class. Epidemiologic studies pointed out higher cancer incidence in iron overload 
individuals compared to iron deplete individuals which shown low incidence of tumor 
formation [130,131]. Iron is an essential element for metabolism and cell cycle progression 
and thus it is particularly required to cancer cells and various studies highlighted that 
association between high iron load and cancer may be due to free radical production and 
reduction in ROS protection mechanisms, or moreover to inhibition to nutrient sensing or 
impairment of immune systems. Gold standard iron chelator was DFO desferoxamine and 
Exjade, used in vitro but also in vivo to treat NB patients in many clinical trials and many 
studies are going on about mechanisms interesting growth inhibition by iron depletion. 
These studies could lead to help in development of new more potent iron chelators with 
low lipophilicity, a characteristic that may interacts with different biochemical processes in 
vitro lead often to side effects [132,133]. 
Due to side effects of non-specific cytotoxic drugs and due to possible selection of chemo-
resistant cellular clones, there is the need to develop novel tumor specific therapies that 
could be less toxic than current approaches and to date, molecular target therapy has 
received much attention. Targets of the molecular therapy are specific molecules 
responsible for cancer progression and thus involved in proliferation, differentiation, 
genetic instability and metastasis [134]. Methods mainly investigated involved peptide 
nucleic acids, which specifically hybridize to DNA or RNA inhibiting transcription or 
translation of a target gene; antisense oligonucleotides that hybridize to and inhibit the 
mRNA of a specific gene and small interfering RNA siRNA, which induces silencing of 
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target genes by inducing degradation of complementary mRNA. Another method consists 
in developing synthetic small molecule inhibitors which potentially show the ability to 
interfere with a molecular target at multiple levels [135]. Synthetic small molecules are 
favored by the pharmaceutical industry because of their attractive pharmacokinetic 
properties, indeed they can easily diffuse into tumor cells inhibit expression of a target 
gene or function of protein. Inhibition is usually due to direct interaction with the specific 
protein preventing its interaction with other factors or inducing conformational changes 
[136]. 
3.1 MYCN as a Therapeutic Target 
Distinct molecular targets have been identified as possible targets for NB treatment and 
great interest was elicited by MYCN oncoproteins. Given its restricted spatial and temporal 
expression limited to the early stages of embryonic development and given its virtually 
undetectable levels in normal post-natal tissues, MYCN could be an elite target for novel 
therapies [5]. Furthermore, MYCN offers multiple levels of targeted inhibition. Different 
research groups have studied downregulation of MYCN in MYCN-amplified NB cell lines 
using different approaches such as PNA or RNAi with variable results depending on 
experimental conditions and cell lines but collectively these studies suggest that target 
MYCN results in growth arrest, apoptosis and/or morphological differentiation [53]. For 
instance, MYCN inhibition through retinoic acid or antisense oligonucleotides has already 
demonstrated to induce neuronal differentiation in NB cells and to reduce tumor growth in 
Neuroblastoma mouse model. [7]. It has been extensively reported that single oncogene 
inactivation within a primary tumor is sometimes sufficient to induce tumor regression, 
thus it is possible to speculate that direct targeting of MYCN could be promising for 
neuroblastoma therapy.  
3.1.1 Target MYCN Transcription  
Recently studied showed MYC suppression after inhibition of the BET bromodomain 
family of chromatin adaptors. Transcription of c-Myc is related to an increased histone 
acetylation, a covalent chromatin modification associated with transcriptional activation. 
BET proteins (bromodomain and extra-terminal family proteins) associate with acetylated 
chromatin facilitating transcriptional activation by increasing the binding of transcriptional 
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activators. A molecule named JQ1 able to target BET proteins was identified. Action of 
JQ1 on c-MYC expression results in preventing the recruitment of coactivator proteins 
necessary for transcriptional initiation and mRNA elongation thus leading to disruption of 
mRNA synthesis. JQ1 treatment in mouse model of multiple myeloma shows its effects on 
tumor burden but treatment on MYCN-amplified NB cell lines and on NB mouse model 
results in MYCN expression decrease, although this effect was far less dramatic than that 
observed in a c-MYC driven cell line [137,138]. 
Thus, another level of MYCN inhibitions could be epigenome regulation. Balance between 
DNA methylation and histone acetylation can be pathologically altered especially in favor 
of DNA hypermethylation and histone deacetylation. Hence, there is a growing interest for 
HDAC inhibitors and many of these are on preclinical trial. For instance, tumorigenesis in 
NB mouse model was decreased after Cambinol treatment, a SIRT1 inhibitor; treatment 
with class I and II HDAC inhibitor, Trichostatin A results in reduced tumor weight and 
volume in the same mouse model [139-1341]. Therefore, HDAC inhibitors may be a viable 
route to target MYCN-amplified NBs. 
3.1.1 Target MYCN Proteins  
Galderisi et al demonstrated a 3-fold decrease in MYCN mRNA levels after antisense 
oligonucleotides treatment in NB cells but phenotypic effects depended on cell lines used. 
After MYCN antisense oligonucleotide treatment, N-types neuronal cells underwent 
differentiation while treatment of Schwannian S-type cells results in both differentiation 
and apoptosis [142]. 
MYCN mRNA inhibition was shown also through treatment with retinoic acid, a vitamin 
A metabolite. Treatment has been shown to induce neuronal differentiation in NB cells in a 
mechanism that involves p27Kip1, a key mediator of growth arrest [143]. 
As described in paragraph 2.1.2 MYC protein proteolysis is a result of subsequential step 
of phosphorylation at multiple sites that involved GSK-3β kinase and PP2A phosphatase 
[75,76]. Inhibition of PI3K can decrease MYCN protein levels through promoting MYCN 
phosphorylation by blocking a PI3K-driven inhibitory GSK-3β phosphorylation [36]. 
Various cancers frequently exhibit alteration in PI3K/mTOR pathway: activation of this 
pathway is related to resistance to apoptosis, increased growth rate and deregulated energy 
supply mechanisms. mTOR inhibitors are known to downregulate MYCN protein and 
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inhibit both in vitro and in vivo NB growth. Moreover, NB cell lines lacking GSK-3β 
phosphorylation site were resistant to treatment with PI3K/mTOR inhibitors [144].  
Another level of MYCN downregulation can be by inhibition of proteins that stabilize 
MYCN proteins. Proteins such as AURKA that prevent dephosphorylation at T58, result in 
stabilizing MYCN through direct protein-protein interaction and making MYCN less 
degradable by proteasome. Interestingly, high levels of AURKA are associated to MYCN-
amplified NBs, mediated potentially by MYCN itself. Thus, AURKA could represent a 
strategy to treat MYCN-amplified NBs, given also its possible ligand binding site. 
Different compounds targeting AURKA have been tested both in vivo and in vitro 
[144,146]. It is also possible that targeting proteins downstream MYCN pathways might be 
an alternative strategy to indirect inhibit MYCN. Indeed, targeting MDM2, for instance 
with Nutlin-3 or MI-63, also results in downregulation of MYCN mRNA blocking its 
expression through inhibitions of MDM2 binding to the 3’UTR of MYCN [147]. 
Despite promising evidence for MYCN as a therapeutic target, no MYC or MYCN 
inhibitors have yet passed the preclinical trial, and further studies are needed to develop 
efficient MYCN inhibitors. 
3.2 Targeting the MYC/MAX/MXD Pathway 
 Site-directed mutagenesis experiments have underlined the critical role of various amino 
acids located within the bHLHz domain in the interactions among MYC/MAX/MXD 
network members. Therefore, it was suggested that the bHLHz domain could be the target 
for therapeutic strategies or for developing inhibitors and several compounds with the 
ability to interfere with MYC-MAX have already been tried. Inhibitors of protein-protein 
interactions are usually designed on the sequence of dimerization domain and often target 
the small discrete binding sites. Impairment of MYC-MAX dimerization through use of 
small-molecule results in decreased c-MYC-induced oncogenic transformation of chicken 
embryo fibroblasts in vitro. The discovery of low molecular weight inhibitors for MYC-
MAX complex has shown that binding between large protein interfaces may also be 
disrupted by small molecules [148]. On the other hand, there is evidence for MYC to 
retains substantial MAX-independent activities, thus this may not be the best strategy for 
all tumor types [109]. 
Endogenous inhibition of MYCN activity was identified after characterization of the 
network which MYC proteins belong to: antagonists such as MAX-MAX dimers have 
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been found to compete for binding to E-box sequences and to indirectly inhibit 
transcription while, antagonists such as MXD/MNT-MAX directly repress transcription of 
MYCN target genes through repression complex recruitment [111]. Strategies to restore 
protein functions are now considered viable anticancer therapeutic approaches and this 
may be an option for MAX-null pheochromocytoma patients or for antagonizing MYCN 
activity in MYCN-amplified NBs [107]. Inhibition of MYC function by exogenous 
antisense approaches, or overexpression of dominant-negative alleles of MNT or MXD 
proteins, severely impairs the growth-factor-induced proliferation of cells in culture [125].  
Evidences reported in paragraph 2.3 highlight the hypothesis that through modulation of 
MYCN/MAX/MXD network it is possible to antagonize MYCN activities. 
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Neuroblastoma (NB) is the most frequently diagnosed malignant solid tumor during 
infancy and affects the developing sympathetic nervous system. While its anatomic pattern 
of origin is well defined, the etiology of NB remains still unclear. Neuroblastoma displays 
profound clinical heterogeneity that reflects the wide differentiation spectrum of the 
neuroblast cells from which it originates. Moreover, NB has also deep genetic 
heterogeneity that is linked to possibility to run into different tumor subtypes that range 
from spontaneous regression to rapid progression and death. The presence of different 
hallmarks allows to divide patients into risk categories. Almost half of all patients at the 
time of diagnosis have stage 4 disease, which represent the more malignant stages with 
presence of hematogenous metastasis.  
About half of high risk NB patients shows MYCN amplification, which is, to date, the 
strongest prognostic indicator of the NB disease. This genetic abnormality is frequently 
found in many types of infancy cancers of mostly neuroendocrine origin, including 
medulloblastoma, astrocytoma, Wilms' tumor, small cell lung cancer, osteosarcoma and 
rhabdomyosarcoma. Moreover, it has been demonstrated that the sole MYCN 
amplification is sufficient to initiate NB formation in mice. 
Given the strong prognostic value of MYCN amplification and its role in driving tumor 
formation, MYCN provides an attractive therapeutic target for treatment of NB. To date, 
many efforts have been made to develop strategies to inhibit MYCN expression and/or 
MYCN-mediated transcription pathways but unsuccessful. This is probably due to the 
presence of MYCN within an intricate network of various proteins named 
MYCN/MAX/MXD protein network whose proteins can bind the same DNA consensus, 
however resulting in both activation or repression.  
As the other MYC oncoproteins, MYCN forms a functional transcription factor when 
associated with another basic helix-loop-helix-leucine-zipper BHLHz protein named MAX 
and carries out its functions as positive modulator of gene involved in proliferation and 
self-renewal. Together with MYCN, MAX belongs to the MYCN/MAX/MXD network of 
transcription factors which interact with each other binding DNA and regulating 
transcription of target genes. Thus, MYCN transcriptional activation is dependent on MAX 
availability. Moreover, MAX can both in vivo and in vitro homodimerize and weakly 
inhibits MYCN target genes. On the other hand, the repressive side of the network is 
represented by MNT-MAX dimers which actively repress transcription of MYCN target 
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genes through its inhibition domain. Thus, the sole MYCN amplification may not exactly 
reflect the biological activity of this factor but MYCN functions are strongly related to the 
expression of MYC/MAX/MXD network proteins. 
Aim of my thesis is to provide a better comprehension of molecular mechanisms 
underlying MYCN oncogenicity to advantage therapeutic approaches to contrast these 
phenomena. Thus, two approaches through which antagonize oncogenic characteristics in 
MYCN overexpressed NB cells have been evaluated. 
A first genetic approach is based on the modulation of the expression levels of MAX and 
MNT network proteins. Published gene arrays on Kocak dataset cohort of 643 patients 
highlight that low levels of MYCN antagonists MAX and MNT in presence of MYCN 
amplification, are related to good clinical outcome. On the other hand, same Kocak dataset 
pointed out correlation between high levels of MAX and MNT and short term survival 
probability in MYCN amplified NB patients.  
Using RNA interference and overexpression in MYCN-amplified cells, we want to 
confirm that downregulation of MAX and MNT suppresses the malignant phenotype of 
NB cell lines, whereas high MYCN antagonist levels correlate with enhancement of the 
malignant phenotype.  
To date, despite the attractiveness of MYCN as a therapeutic target and the discovery of 
new MYCN targeting compounds, most of them have not passed the pre-clinical stage 
because of their non-specificity or selection of resistant clones. A second approach through 
elucidate mechanisms underlying the MYCN-driven oncogenicity is based on the study of 
a new compound isolated for its ability to downregulate MYCN only in actively 
proliferating cells. To better characterize action of M606, the novel iron chelator derivative 
of hydroxyquinolones isolated, reporter gene assay was used to test compound action on 
MYCN promoter. 
Through chromatin immunoprecipitation, chromatin status has been investigated and 
moreover, through comparison with Exjade, another iron chelator used to treat NBs, it was 
investigated whether this may be or not a generalized mechanism related to iron chelator 
class of compounds. 
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1 Genetic Modulation of the MYCN/MAX/MXD Network 
1.1 Expression of MAX and MNT in MYCN-amplified Neuroblastoma is 
related to short event free survival probability 
MYCN amplification is predictive for clinical outcome in NBs but MYCN can form a 
functional transcription factor only when associated with MAX, Moreover, MAX 
availability firmly depends on the expression levels of other network members, such as 
MNT. Thus, the sole MYCN amplification can not exactly reflect the biological activity of 
this factor but MYCN functions are strongly related to the expression of MYC/MAX/MXD 
network proteins. 
To understand how MAX and MNT expression impact on Neuroblastoma, experimental data 
present in published gene expression arrays were evaluated. Genomics analysis and 
visualization R2 platform (http://r2.amc.nl) were used to evaluate a possible correlation 
between MYCN amplification and MNT or MAX expression in Neuroblastoma. Thus, meta-
analysis was conducted using publically available microarray based on Kocak gene 
expression datasets which profiles a cohort of 649 NB tumors stratified for age and sex, 
presence of MYCN amplification and stage of disease. Data were graphed as survival 
probability without relapse events (event free survival EFS) [149].  
As shown in figure 1.C, high levels of MAX and MNT in MYCN amplified NB patients are 
strongly related to short term event free probability. When data are plotted without taking in 
account MYCN stratification, MAX and MNT high expression loses its correlation with 
poor clinical outcome, and in contrast seems that their expression has a favorable prognostic 
impact both in mixed NBs and in MYCN-not amplified NBs (Fig.1 A shows MYCN not 
amplified NBs while Fig.1B shows mixed cohort of NBs). 
Based on these intriguing findings, it was hypothesized that it is not the exclusive MYCN 
expression to determine poor prognosis, but a displacement in the members of the network 
in such a way that prognosis may depend on the fine balance between MYCN and its 
counterparts. 
Thus, it has been decided to elucidate how modulation of expression levels of MAX and 
MNT may define cellular behaviors in MYCN-mediated tumorigenesis. 
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Fig.1. Kaplan–Meier curve estimates for EFS according to classification by the SVM_th10 predictor. Red curves represent 
low mRNA expression, while blue curves represent high mRNA expression. Characteristic of the involved patients are 
defined in ref [149]. Published data derived from R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl) 
database.   
A. The MAX (left) and MNT (right) relative Kaplan–Meier survival EFS for the sub-cohort of Neuroblastoma patients 
stratified for the absence of MYCN amplification (n = 476); 
B. The MAX (left) and MNT (right) relative Kaplan–Meier survival EFS for the complete validation cohort of patients 
with neuroblastoma (n = 405); 
C. The MAX (left) and MNT relative Kaplan–Meier survival EFS (right) for NBs patient sub-cohort showing MYCN 
amplification (n=66). 
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1.2 Suppression of the malignant phenotype in MYCN-amplified NB cell 
line by knockdown of MAX and MNT  
1.2.1 Silencing of MAX and MNT in BE(2)-C induces cell growth rate decrease 
through upregulation of p21 Cip1 
Tumorigenesis is the result of cell cycle deregulation, leading to an uncontrolled cellular 
proliferation. MYCN, together with its essential dimerization partner MAX, has an 
important role in transcriptional regulation of gene whose products are involved in 
proliferation. Moreover, MNT protein expression is coincident with that of MYC, regardless 
of cell cycle and differentiation [118,122]. 
To further examine the hypothesis that the modulation of the network members could change 
NB biological features in response to MYCN amplification status, SK-N-BE(2)-C NB cell 
line (here named BE(2)-C) were transducted with lentivirus expressing shRNA against 
MAX and MNT and a control shRNA and growth rate was evaluated. Specifically, 5 
shRNAs against each factor were tested in MYCN-amplified BE(2)-C cells and validated 
through qRT-PCR and western blot and the most efficient was chosen (data not shown). 
After transduction with the most active shRNA, knockdown was validated through Western 
blot and qRT-PCR (Figure 2.A and 2.B). 
Proliferation was evaluated through automated cell counter via stains propidium iodide 
stains of nucleic acid and 24 hours were chosen as time points. Plotted in figure 2.C growth 
curve indicating that knockdown of MAX and MNT strongly reduce cell number through 
days.  
p21Cip1 is a potent cyclin-dependent kinase inhibitor 1 that inhibits CDK2 and CDK1 
complexes and thus, mediates cell cycle G1 phase arrest. It is also known to be down-
modulated in the majority of NBs and p21Cip1 expression induced significant neurite 
extension in neuroblastoma cells. Figure 2.D shows a strong upregulation of p21Cip1 mRNA 
levels after MAX knockdown. MNT downregulation can also induce increase in p21Cip1 
mRNA in BE(2)-C although less dramatically. 
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Fig.2.Genetic silencing of MAX and MNT reduces malignant phenotype in NB MYCN-amplified cell line impairing cell 
proliferation. BE(2)-C were transducted with scramble shRNA and shRNA against MAX and MNT, followed by 
selection with 1ugr/mL with puromycine. All data shown as mean of at least 3 independent experiments ± standard error 
of the mean (SEM). Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni's 
post hoc test; *, ** and *** indicate P<.05, .01 and .001 respectively. NS not statistically significant.  
A. Western blot on MAX and MNT knockdown BE(2)-C. 
B. qRT-PCR on MAX and MNT mRNA. White bar indicates control shRNA sample, bright and dark gray are respectively 
MNT and MAX shRNA samples. Internal reference gene was GlUcuronidaSeBeta, GUSB; 
C. Silencing of MAX and MNT impairs cell proliferation. Cell growth rate of each groups were assessed by cell counting 
every 24 hours and expressed as number of cells per well; 
D. qRT-PCR showing p21 increased value after shRNA transduction. White bar indicates control shRNA sample, bright 
and dark gray are respectively MNT and MAX shRNA samples. Internal reference gene used was GlUcuronidaSeBeta, 
GUSB. 
1.2.2 RA promotes differentiation in MAX- and MNT KD BE(2)-C  
Grade of differentiation is a measure of cancer progression and MYCN is known to be a 
regulator of a set of genes involved both directly and indirectly in neuronal differentiation 
processes [8]. NB cells retain some features of neural crest progenitors, such as the ability 
to undergo neuronal differentiation in the presence of appropriate signals such as Retinoic 
Acid.  
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To further understand how MAX and MNT knockdown can affect cellular behaviors of 
MYCN-amplified NB cells, the capability of cells to undergo differentiation was evaluated 
after stimulation with 10µM of Retinoic Acid RA, a derivative of vitamin A.  
Expression levels of the neuronal marker genes neuromodulin (GAP43) and neurofilament 
middle chain (NEFM) and morphological signs of differentiation in response to RA 
treatment were evaluated. Neuronal differentiation includes the elaboration of a large 
network of axons and dendrites, which are referred non-specifically as neurites when grown 
in culture. Thus, after seeding cells at proper density, medium was replaced every day with 
fresh medium with addition of RA. Morphological changes were evaluated every 24 hours.  
Average length of the neurites was obtained by manually tracing the length of all neurite 
outgrowths from neuron’s cell body using NIH-ImageJ software. Total number of neurites 
were divided by the total number of cells present. 
Results demonstrate that BE(2)-C knockdown of MAX induces the most typical 
morphological changes observed during neuronal differentiation. Figure 3.A shows a strong 
increase in neurite extension already after 3 days of RA treatment and moreover these cells 
shows decreased neurite branching (Figure 3.B) and decreased cell numbers (Figure 3.C). 
Left panel of Figure 3.D underline the typical neurite alignment shown by MAX-KD cells. 
On the other hand, downregulation of MNT in BE(2)-C seems not to induce morphological 
changes associated with neuronal differentiation. 
Through analysis of the two neuronal markers GAP43 and NEFM, we investigated whether 
RA treatment could lead cells to undergo differentiation into neuronal like cells.  NEFM is 
middle-molecular-weight neurofilament protein that comprises the axoskeleton and is 
usually associated with axonal neurite caliber and commonly used as a biomarker of 
neuronal damage. GAP43 or neuromodulin is a marker of an effective regenerative response 
in the nervous system associated with nerve growth and filopodia induction. Results 
indicated in figure 3.E indicate that RA induction of differentiation leads MAX- and MNT-
KD cells to express high levels of GAP43 but relatively low levels of NEFM. 
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Fig.3.Genetic silencing of MAX leads to retinoic acid-induced neurite formation in BE(2)-C transducted with scramble 
shRNA and shRNA against MAX and MNT. All data shown as mean of at least 3 independent experiments ± SEM standard 
error of the mean. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni's post 
hoc test; *, ** and *** indicate P<.05, .01 and .001 respectively. NS not statistically significant.  
A. Average neurite length after 3 and 6 days of 10µM RA treatment plotted as percentage of the control; 
B. Average number of neurites after 3 and 6 days 10µM of RA treatment plotted as percentage of the control and normalized 
on cell numbers; 
C. Average number of cells following 3 and 6 days of 10µM of RA treatment plotted as percentage of the control and 
normalized on cell numbers; 
D. Morphological features of shRNA cells after 6 days of 10µM RA. Panel on the left shows shMAX cells with an increased 
neurite alignment. Panel in the middle represents control and panel in the right indicates shMNT cells; 
E. qRT-PCR on transducted cells. Purple panel in the left indicates NEFM mRNA level while green panel on the right 
represents GAP43 mRNA expression levels. Light gray bar indicates control shRNA sample. X axis indicates days of RA 
induction. Internal reference gene used was GlUcuronidaSeBeta, GUSB. 
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1.2.3 Silencing of MAX and MNT induces differential expression of the main 
prognostic markers 
 
The Trk family of neurotrophin signaling receptors are strongly related to differentiation 
grade of NB tumors and in vitro are strong signals promoting neurite outgrowth. Expression 
of neurotrophin receptor TRKA and NGFR is commonly found in favorable NBs and are 
considered as positive prognostic marker of the disease. MYCN/SP1/Miz1 complex is 
known to target core promoter of TRKA and NGFR genes to induce repressed chromatin 
status and thus, downregulation of the two receptors. Moreover, NGFR and TRKA are 
considered a marker of early and immature neuronal differentiation [150,151]. 
To further characterize MAX and MNT knockdown, neurotrophin signaling receptors have 
been evaluated. Figure 4.A indicates a strong upregulation of the two neurotrophin receptors 
TRKA and NGFR in presence of a weaker reduction of MYCN mRNA level when both 
MAX and MNT were downregulated in BE(2)-C. All these findings strongly correlate with 
the gene expression arrays on figure 1.C based on clinical data which show correlation 
between high survival probability and MAX or MNT low levels in MYCN-amplified NBs.  
Although direct correlation of TRKA/NGFR with positive clinical outcome, the 
neurotrophin signaling receptors TRKB is preferentially expressed together with its ligand 
BDNF in NBs with poor prognosis. Their expression provides invasive and metastatic 
capability to tumor cells and moreover, there are lines of evidence that BDNF/TRKB 
signaling in NB cells is known to enhance therapy resistance. Results shown in figure 4.B 
indicates upregulation of TRKB mRNA in MNT-KD cells but in absence of any BDNF 
increase thus, no autocrine pathway of BDNF/TRKB signaling is activated.   
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Fig.4. MAX and MNT knockdown induces high expression of TRKA and NGFR neurotrophin receptors in BE(2)-C. All 
data shown as mean of at least 3 independent experiments ± SEM standard error of the mean. Statistical analysis was 
performed using one-way analysis of variance (ANOVA) with Bonferroni's post hoc test; *, ** and *** indicate P<.05, .01 
and .001 respectively. NS not statistically significant. Internal reference gene used was GlUcuronidaSeBeta, GUSB.  
A. qRT-PCR of positive prognostic markers compared to MYCN expression level on transducted cells. Light gray bar 
indicates control shRNA sample. X axis indicates mRNA analyzed. Samples are indicated on legend; 
B. qRT-PCR of negative prognostic markers on transducted cells. Light gray bar indicates control shRNA sample. X axis 
indicates mRNA analyzed. Samples are indicated on legend. 
 
Among other prognostic markers, metalloproteinases and their inhibitors were analyzed. 
Extracellular matrix proteolysis and degradation depend on the net ratio between matrix 
metalloproteinases and their tissue inhibitor metalloproteinases TIMP. Increased expression 
in NBs of MMP-2 in association with low levels of TIMP-2 is associated with poor clinical 
outcome and advanced clinical stages [152]. 
 
Fig.5. MAX and MNT silencing in BE(2)-C induces no change in MMP-2/TIMP-2 ratio before RA treatment and enhanced 
TIMP2 expression after RA treatment. All data shown as mean of at least 3 independent experiments ± SEM standard error 
of the mean. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni's post hoc 
test; *** indicates P<.001. Internal reference gene used was GlUcuronidaSeBeta, GUSB.  
A. qRT-PCR on transducted cells before retinoic acid treatment. Light gray bar indicates control shRNA sample. X axis 
indicates MMP and TIMP mRNA analyzed. Samples are indicated on legend. Data are not statistically significant compared 
to control shRNA; 
B. qRT-PCR on transducted cells after 6 days of retinoic acid treatment shows enhanced TIMP2 expression. Light gray bar 
indicates control shRNA sample. X axis indicates MMP and TIMP mRNA analyzed. 
 
Results indicated in figure 5.A shows that MNT- and MAX-KD cells do not induce change 
in MMP-2/TIMP-2 ratio, but after induction of differentiation with retinoic acid, balance is 
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strongly shifted towards TIMP-2 expression with the strongest effect for MAX-silenced NB 
cells compared to control.  
On the other hand, MMP-9 seems not to be associated with NB clinical stage and prognosis 
and it is usually not expressed in neuroblastoma cells but rather from stromal cells. It is 
known that MMP-9 promotes differentiation of adult neural progenitor cells and in mouse 
model of MYC-induced pancreatic neuroendocrine tumors, MMP-9 knockdown promotes 
tumor invasion [152-154].  Moreover, RA treatment is known to promote MMP-9 in SK-N-
BE neuroblastoma cell line in association with phenotypic neuronal-like differentiation BE 
neuroblastoma cell line in association with phenotypic neuronal-like differentiation [155]. 
Figure 6 indicates that knockdown of MAX and MNT leads to expression of MMP-9 and 
this expression is enhanced after RA treatment compared to control.  
                                             
Fig.6. qRT-PCR on transducted BE(2)-C cells shows that MAX and MNT Knockdown induces expression of MMP-9 
before RA treatment (DAY 1) and RA treatment further enhanced its expression. All data shown as mean of at least 3 
independent experiments ± SEM standard error of the mean. Statistical analysis was performed using one-way analysis of 
variance (ANOVA) with Bonferroni's post hoc test; **, *** indicate P<.01 and .001. Internal reference gene used was 
GlUcuronidaSeBeta, GUSB.  
1.2.4 Knockdown of MAX in BE(2)-C impairs BE(2)-C motility 
To strengthen the evidence that modulation of MAX and MNT protein levels may affect 
cellular behaviors, motility activity was evaluated through wound closure assay. Results in 
in figure 7.A and B pointed out that downregulation of MAX strongly impairs migratory 
activity of BE(2)-C, whereas MNT knockdown do not impair motility. 
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Fig.7. Knockdown of MAX impair motility of BE(2)-C transduced cells as measured by wound closure assay for 36 hours, 
compared with scramble shRNA cells. All data shown as mean of at least 3 independent experiments ± SEM standard error 
of the mean. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Bonferroni's post hoc 
test; *** indicated P<.001. NS not statistically significant.  
A.  Representative images of wound closure assay;  
B.  Wound closure assay on BE(2)-C transducted with shRNA against MNT (light gray) and MAX (dark gray) expresses 
as percentage of repair. Samples are listed in legend. 
1.3 Upregulation of MAX and MNT protein levels enhances the malignant 
phenotype of BE(2)-C 
As previously mentioned and indicated in figure 1.A and 1.B, high levels of MAX and MNT 
in MYCN amplified NB patients are strongly related to bad prognosis. Thus, it was pointed 
out that it is not the exclusive MYCN expression to determine poor prognosis, but a 
displacement between MYCN and its network counterparts. To strengthen the hypothesis 
that through the modulation of the network members it is possible to counteract MYCN 
oncogenicity, MAX and MNT were overexpressed in MYCN amplified NB cell line.  
1.3.1 Overexpression of MAX and MNT in BE(2)-C leads to increased 
proliferation rate 
Specifically, BE(2)-C were transfected with constructs bearing MNT and long and short 
isoforms of MAX, here named respectively MAXL and MAXS. To distinguish ectopic from 
endogenous expression, all proteins were conjugated with a flag.  
Effective overexpression was validated through Western blot analysis (figure 8.A). 
Proliferation rate was evaluated as previously mentioned for MNT and MAX knockdown. 
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Analysis conducted reveal that expression of MAXL and MNT in BE(2)-C leads to a 
strongly increase in growth rate. On the other hand, overexpression of MAXS induces no 
change in proliferation rate of BE(2)-C (figure 8.B) 
Through qRT-PCR, p21 Cip1 mRNA levels were evaluated and results indicate a strong 
downregulation in both MNT and MAXL overexpressing cells, whereas overexpression of 
MAXS results in no change in p21 Cip1 mRNA levels (figure 8.C). 
 
Fig.8. Transient overexpression of MAXL and MNT in BE(2)-C induces change in proliferation rate. All data shown as 
mean of at least 2 independent experiments ± SEM standard error of the mean. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) with Bonferroni's post hoc test; **, *** indicate P<.01 and .001 NS not statistically 
significant.  
A.  Western blot analysis validates MAXL, MAXS and MNT overexpression and their inducible decreased level after 
addition of tetracycline;  
B.  Overexpression of MAXL and MNT induce high proliferation rate compared to tetracycline treated cells. Cell growth 
rate of each group were assessed by cell counting every 24 hours and expressed as number of cells per well; 
C. qRT-PCR showing p21 decreased value after 48 hours of MAXL and MNT overexpression. Light gray bar indicates 
control empty vector sample, other samples are listed in legend. Internal reference gene used was GlUcuronidaSeBeta, 
GUSB. 
Results 
 
 48 
 
1.3.2 Effect of RA treatment in MAXL, MAXS and MNT overexpressing cells 
To better characterize the role of MAX and MNT overexpression in determining cellular 
behaviors of MYCN-amplified NB cells, the capability of transfected cells to undergo 
differentiation was evaluated. After stimulation with 10µM of Retinoic Acid, morphological 
signs of differentiation and expression levels of the neuronal marker genes GAP43 and 
NEFM were evaluated. Average length and total number of neurites per number of cells 
were obtained as previously described. 
Results indicate that when MAXS and MNT were overexpressed no significant 
morphological change was appreciated, whereas overexpression of MAXL results in a slight 
decrease in neurites formation. MYCN-amplified NB tumors and cell lines present up to 100 
fold increase of MYCN expression levels and in particular, BE(2)-C are 4-stage tumor cells 
deriving from bone marrow metastasis with MYCN-HSRs and thus considered highly 
malignant cell type [5]. Worsening its cancerous phenotype grade seems to be a hard effort, 
especially using a transient system.  
Fig.9. Transient overexpression of MAXL and MNT in BE(2)-C do not induce change in neurite length. All data shown 
as mean of at least 2 independent experiments ± SEM standard error of the mean. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) with Bonferroni's post hoc test; NS not statistically significant.  
Effect of 10µM of RA treatment on MAXL, MAXS and MNT overexpressing cells. Upper left panel shows average of 
neurite length plotted as percentage of the control. Upper right panel shows number of neurites plotted as percentage of 
control and normalized on cell numbers. All data are NS. Lower panel shows number of cells after RA treatment. All data 
are normalized on tetracycline treated samples. All data are NS. 
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From analysis of neuronal differentiation markers GAP43 and NEFM emerges the different 
role of MAX long and short isoforms. When BE(2)-C are transfected with MAXS, all two 
neuronal markers are strongly expressed thus suggesting a protective and pro-differentiative 
role. On the other hand, MAXL overexpression do not to impair neuronal marker expression. 
In MNT overexpressing cells, all two neuronal marker mRNA levels were found 
significantly decreased suggesting an opposite role for MAXS and MNT. 
                
Fig.10. Transient overexpression of MAXL and MNT in BE(2)-C induces change in neurite length. All data shown as 
mean of at least 2 independent experiments ± SEM standard error of the mean. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) with Bonferroni's post hoc test; *, **, *** indicate P<.05, .01 and .001. NS not 
statistically significant.   
qRT-PCR on transducted cells. Purple panel on the left indicates NEFM mRNA level while green panel on the right 
represents GAP43 mRNA expression levels. Light gray bar indicates control EV sample. Internal reference gene used was 
GlUcuronidaSeBeta, GUSB. 
1.3.3 Overexpression of network members affects prognostic markers inducing gain in 
migratory capability 
NGFR and TRKA are considered markers of early and immature neuronal differentiation 
[150,151]. Given the role of TRKA and NGFR in promoting in vitro neurite outgrowth and 
given their expression in favorable NBs, to better characterize MAX and MNT 
overexpressing cells TRKA and NGFR mRNA levels were evaluated.  
Results indicate that both TRKA and NGFR mRNA expression was found significantly high 
after transient expression of MAX short isoform, thus strengthening the hypothesis of the 
protective MAXS role compared to MAXL. To reinforce this evidence, expression of 
TRKB, commonly found in poor prognosis NBs, is significantly high in MAXL and MNT 
while not in MAX short isoform. 
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Another intriguing finding that emerges from analysis of neuronal and positive prognostic 
markers is the opposite role of MAXS and MNT: as shown for GAP43 and NEFM, also 
TRKA and NGFR were found significantly decreased after MNT overexpression and not 
after MAXS overexpression. Modulation of neurotrophin signaling receptors occurs without 
any change in MYCN levels. 
 
Fig.11. qRT-PCR of positive prognostic markers compared to MYCN expression level on transducted cells. Light gray 
bar indicates control sample. X axis indicates mRNA analyzed. Samples are indicated on legend; All data shown as mean 
of at least 2 independent experiments ±SEM standard error of the mean. Statistical analysis was performed using one-way 
analysis of variance (ANOVA) with Bonferroni's post hoc test; *, ** and *** indicate P<.05, .01 and .001 respectively. NS 
not statistically significant. Internal reference gene used was GlUcuronidaSeBeta, GUSB.  
 
Migratory activity was then investigated through wound closure assay.  
Results underline that overexpression of MAXL and MNT induce a slightly trend in increase 
motility capability of BE(2)-C, whereas overexpression of MAXS do not impair motility. 
 As previously point out, BE(2)-C are highly malignant tumor cells with a replicative cell 
cycle of 18 hours (data from ATCC Standards Development Organization) that makes it 
difficult to analyze a predicted more malignant phenotype. 
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Fig.12. Wound closure assay for 36 hours, compared with tetracycline-treated cells. All data shown as mean of at least 2 
independent experiments ±SEM standard error of the mean. Statistical analysis was performed using one-way analysis of 
variance (ANOVA) with Bonferroni's post hoc test; NS not statistically significant.  
A.  Representative images of wound closure assay;  
B.  Wound closure assay on BE(2)-C transfected with MAXL(left orange panel), MAXS (middle green panel) and MNT 
(right blue panel) and expresses as percentage of repair. 
 
 
 
2 Pharmacological Modulation of the MYCN/MAX/MXD 
Network 
Conventional approaches to treat NB involved surgery, radiotherapy and especially 
administration of non-specific cytotoxic drugs that lead to high incidence of side effects due 
to high grade of aspecificity. Here resides the need to develop novel less toxic molecular-
target therapy. There are many clinical trial testing drugs that target various molecules but 
the most attractive molecule to target remains MYCN. The rationale for choosing MYCN as 
a therapeutic target for treatment of neuroblastoma lies firstly in its deregulated expression 
in highly malignant tumors, and moreover, MYCN amplification is associated with patient 
poor clinical outcome. Additionally, its expression in normal tissue is restricted to the early 
stages of embryonic development, and is virtually undetectable in normal adult tissues.  
To date, despite the attractiveness of MYCN as a therapeutic target and the discovery of new 
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MYCN targeting compounds, most of them have not passed the pre-clinical stage because 
of their non-specificity or selection of resistant clones. 
 
 
2.1 Chemical library screening identifies M606 as MYCN inhibitors  
From the collaboration with the research group of Dr. Michelle Haber (Children’s Cancer 
Institute, Australia, Sidney) a chemical library comprising 34.000 molecules were screened 
and a derivative of hydroxyquinolones named M606 was isolated for its strong ability to 
downregulate MYCN both at protein and mRNA level as shown in Figure 12.C and for its 
ability to reduce oncogenic behaviors of NB MYCN amplified cell lines (data not shown). 
Then, it was questioned if M606 may act by inducing change in MYCN mRNA or protein 
stability. For this purpose, BE(2)-C were treated with cycloheximide, inhibitor of proteic 
synthesis and with Actinomycin D, an antibiotic inhibitor of DNA synthesis. At regular time 
points, respectively total protein samples and mRNA samples were evaluated through 
Western blot and qRT-PCR analysis. Panel D of Figure 12 illustrates that M606 does not 
induce change in protein or mRNA decay time and since there is no change in stability, it 
was therefore hypothesized that it can act at transcriptional level. 
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Fig.13. Screening on a large chemical library of unique compounds in a cell-based readout system leads to identification 
of M606.    
A. Identification of M606 compound for its ability to decrease MYCN protein level compared to other drugs tested. Here 
represented just few compounds tested on BE(2)-C; 
B. Cytotoxicity assay on different NB MYCN-amplified cell lines with increasing concentration of M606; 
C. M606 can strongly decrease MYCN levels. BE(2)-C treated with 15µM of M606  for the listed time points. Left panel: 
Western blot analysis; right panel: qRT-PCR expressing MYCN levels as percentage of control; 
D. MYCN mRNA levels plotted as a function of time after M6 treatment and after the addition of actinomycin D. In red 
are shown treated sample decay while in black mRNA levels of cells treated with DMSO as control; 
E. MYCN protein levels plotted as a function of time after M6 treatment and after the addition of cycloheximide. In red 
are shown treated sample decay while in black protein levels of cells treated with DMSO as control. 
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2.2 M606-mediated MYCN downregulation depends on cell density 
 
Sensitivity to pharmacological treatments could be dramatically different depending on cell 
confluency. Many cancer chemotherapy agents selectively kill actively dividing cells 
therefore sub-confluent cell cultures while sparing cells that are not dividing. Since the gene 
expression patterns of growing and cell cycle arrested cells are different, this can also result 
into selective expression of membrane transporters, metabolizing enzymes, or binding 
proteins that could affect pharmacological treatment. On the other hand, many drugs have 
similar effect in confluent as well as in sub-confluent conditions. M606 action on MYCN 
protein is effective only in actively proliferating cells. 
                                   
Fig.13. Western blot analysis on BE(2)-C to test action of M606 on cell confluence; actin was used as internal control. 
 
2.3 M606-mediated MYCN downregulation can be reverted by iron 
addition 
M606 is a derivative of hydroxyquinolones which shows ability to chelate iron. To date, 
main drugs targeting MYCN that passed the pre-clinical trial belong to iron chelator class. 
Epidemiologic studies pointed out higher cancer incidence in iron overload individuals 
compared to iron deplete individuals which shown low incidence of tumor formation 
[130,131]. Iron is an essential element for metabolism and cell cycle progression and thus it 
is particularly required to cancer cells.  
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Fig.14. Right panel shows qRT-PCR on BE(2)-C treated with 15µM of M606. Western blot analysis on treated cells is 
shown on left panel; actin was used as internal control. 
2.4 M606-induced MYCN downregulation occurs through decrease in 
chromatin acetylation pattern and iron addition restores acetylation status 
of chromatin  
To better understand the mechanisms of M606 action on MYCN expression, acetylation 
status of MYCN promoter was analyzed. Histone acetyltransferases HATs act 
antagonistically to HDACs to control chromatin accessibility for gene transcription. Also, 
DNA methylation works in gene silencing allowing densely packing of DNA and thus, 
lowering gene expression. Moreover, recent findings have shown that various tumors as 
NBs, show recurrent genetic mutations converging on epigenetic mechanisms. To define the 
epigenetic mechanisms that drive the M606-mediated MYCN downregulation, chromatin 
immunoprecipitation (ChIP) was performed using H3 pan-acetylated antibody on BE(2)-C 
treated for 12 hours with 15µM of M606. Results highlight role of acetylation and not in 
methylation in MYCN downregulation induced by compounds. ChIP shows a decrease in 
acetylation that can be blocked by addition of equimolar of iron (figure 14.A and B). 
 DNA methylation pattern was further investigated performing a methylated DNA 
immunoprecipitation using an antibody raised against 5-methylcytosine (5mC). Results 
show no change in methylation after M606 treatment (figure 14.C and D). 
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Fig.15. Acetylation and methylation pattern of MYCN promoter after 12h of M606 treatment. Mean of two independent 
experiments ±SEM standard error of the mean. Data are presented as fold enrichment normalized on enrichment obtained 
using pre-immune serum (IgG).  
A. ChIP on MYCN promoter of BE(2)-C treated with 15µM M606 and with equimolar of FeSO4. GAPDH promoter is 
used as positive experimental control. 
B-C. Western blot analysis on ChIP sample (B) and MeDIP sample (D). Actin was used as internal control. 
D. MeDIP on MYCN promoter of BE(2)-C treated with 15µM M606. LDH is used as positive experimental control. 
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2.5 Identification of the minimum M606 responsive region  
Since M606 induces no change in MYCN protein and mRNA stability, but rather its 
inhibition leads to a decreased acetylation pattern, it was hypothesized that it can act at 
transcriptional level. To support this hypothesis, a reporter gene assay was used to evaluate 
M606 action on MYCN promoter.  
 
 
 
2.5.1 Identification of the minimum M606 responsive region in the MYCN 
promoter 
 
MYCN promoter was cloned upstream luciferase firefly coding sequence and the activity of 
MYCN_LUC construct after 12 hours of M606 treatment was tested. BE(2)-C were 
cotransfected with MYCN promoter_LUC construct and a construct carrying another 
luciferase that acts as internal calibrator of the system. In figure 15, it is shown the workflow 
of the analysis and the related graphs. Given the existence of two MYCN mRNAs from 
RefSeq, 2.9Kb comprising all two putative MYCN promoters were analyzed. Figure 15.A 
shows the three constructs used comprising the two MYCN promoter and the whole 2.9kb 
construct. Through a reporter gene assay all constructs were tested for their ability to drive 
LUC transcription. Data are reported as ratio between treated on not treated, normalized on 
values of exon 62 of dystrophin and expressed in RLU or relative light units. 
Results indicate that the action of M606 on the construct -1385;-2 of MYCN promoter leads 
to a strongly decrease in luciferase activity. As consequence, also the whole MYCN 
promoter respond to M606 action (figure 15.B) 
Consequently, to verify the possible existence of one or more M6 responsive regions, 9 
deletion constructs were generated and tested. These constructs were designed to have 200 
bp of serial deletions with 50 bp overlapped (Figure 15.C) . After BE(2)-C transfection and 
M606 treatment, it was identified construct with deletion 8 as responsible of M606 action 
on MYCN promoter. Absence of this region in the MYCN promoter lead to M606 
insensitivity and thus result in no RLU variation (Figure 15.D). Also construct with deletion 
9 shows a partially insensitivity to M606 action therefore it was decided to test all 200bp 
that were deleted in constructs 8 and 9 and moreover to test a negative random region of the 
MYCN promoter (Figure 15.E right panel).  
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Fig.16. Workflow and dual luciferase assay. Luciferase activity is expressed in RLU. Data are represented as mean of at 
least 3 independent experiments ±SEM standard error of the mean. Data were normalized on exon 62 of dystrophin DMD. 
All grey bar represents negative controls.  
A. Schematic representation of the three MYCN promoter tested; 
B. Dual luciferase reporter assay on BE(2)-C after 12 hours of 15µM M606 action. Constructs tested are represented in 
red; 
C. Schematic representation of the 9 deletion constructs tested; 
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D. Dual luciferase reporter assay on BE(2)-C after 12 hours of 15µM M606 action. Whole MYCN promoter in red is used 
as positive control. In green are represented all deletion constructs; 
E. Schematic representation of the three regions of 200pb of MYCN promoter tested on the left panel. Right panel shows 
dual luciferase assay of the three construct. Whole MYCN promoter in red is used as positive control. Dark green bars 
indicate construct carrying 200pb deleted in construct 8 and 9; 
F. Dual luciferase reporter assay on BE(2)-C after 12 hours of 15µM M606 action. Constructs carrying region deleted in 
construct 8 and 9 were used as positive control (dark green). Constructs carrying the 50 overlapped bp are represented in 
turquoise; 
G. In silico analyses of putative transcription factors performed with different homology degree. 
 
The presence of random region upstream the luciferase gene does not yield any M606 
response, whereas the presence of the 200bp deleted in constructs 8 and 9 lead to a strongly 
decrease in luciferase activity thus suggesting their role in M606-mediated MYCN 
downregulation (Figure 15.E left panel). As previously mentioned, two constructs have 50bp 
in common and this suggest that the putative involved region may span this region. 
Therefore, 50pb were cloned and tested through reporter assay and result evident in Figure 
15.F its involvement in mediate M606 action on MYCN promoter. To identify putative 
factors involved whose consensus span this 50bp, in silico analyses were performed using 
Predicted Prokaryotic Regulatory Proteins P2RP software (figure 16.G) [157]. Analysis 
performed filtered for transcriptional factors with 99% of homology revealed 2 E2F 
consensus and stat4 and YY1 consensus sequences. 
 
 
 
2.5.2 M606 action on MYC protein and identification of homology sequence 
between MYC and MYCN 
 
Interestingly, results in figure 16.A indicate that compound acts also on cMYC inducing a 
decrease in its expression in different NB cell lines but also non-neuronal cell line as HepG2 
(data not shown). Given this evidence, a further in silico analysis was performed to identify 
a common region between MYCN and cMYC promoter and a region of 24bp comprising 
three E2F sites, two of which are inversely oriented and overlapped and one TIE 
TGFb inhibitory element was identified (figure 14.B). This region spans 24 bp upstream of 
the multiple transcription start site, which is highly conserved in the human and mouse MYC 
genes and mediate major part of promoter activity and responsiveness to TGFb [80]. Thus, 
to better define the role of this sequence in mediate M606 action, 3 further constructs were 
created and tested. The first construct has whole MYCN promoter sequence except the 
putative 24bp, while second and third constructs comprise whole MYCN promoter except a 
Results 
 
 60 
deletion of respectively the two inversely oriented and overlapped E2F sites and E2F/TIE 
sites. 
Results underline that deletion of the whole E2Fs/TIE sites and deletion of the E2F1-2 
consensus from the whole 1383bp of MYCN promoter disrupt the action of M606 on MYCN 
thus strongly supporting the hypothesis of E2F involvement in MYCN downregulation 
(figure 16.C). Given the derivation of BE(2)-C from stage 4 treated patients, it was 
questioned if this could be a generalizing mechanism of action or it could be BE(2)-C 
specific. 
To strengthen the hypothesis of generalizing mechanism involving E2Fs in M606 
downregulation of MYCN, the same assay was performed also in another neuroblastoma 
cell line LAN1 obtaining same result (Figure 16.D). 
 
Fig.17. Identification of homology sequence between MYC and MYCN. Data are represented as mean of at least 3 
independent experiments ±SEM standard error of the mean. Data were normalized on exon 62 of dystrophin DMD. All 
grey bar represents negative controls.   
A. Western blot analysis performed on SH-SY5Y and SH-EP after 12 hours of 15µM M606 treatment; 
B. Schematic representation of the homology sequence between MYCN and cMYC promoter region; 
C. Dual luciferase assay performed on BE(2)-C transfected with deletion variants of the whole MYCN promoter. MYCN 
whole promoter was used as positive control (dark red) data are normalized on exon 62 of DMD. In purple is represented 
construct with E2Fs/TIE deletion. In pink construct with E2F1/E2F-2 site deletion and in light pink construct with 
E2F3/TIE deletion; 
D. Upper panel shows 15µM M606 action on MYCN in LAN1 after 12 hours of treatment. Lower panel shows dual 
luciferase assay performed on LAN1 transfected with deletion variants of the whole MYCN promoter. MYCN whole 
promoter was used as positive control (dark red) data are normalized on exon 62 of DMD. In purple is represented construct 
with E2Fs/TIE deletion. In pink construct with E2F1/E2F-2 site deletion and in light pink construct with E2F3/TIE deletion. 
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2.6 Downregulation of MYCN involved dephosphorylation of RB protein 
and change in RB pathway related genes 
E2F proteins regulate various target genes involved in various mechanisms such as DNA 
repair, cell cycle progression or apoptosis that finely regulate the balance between growth 
promotion and suppression.  The 8 E2F members can be classified into different subgroups 
based on their structure, affinity for different members of pRB family and putative function. 
Members of the activator subgroup which consists of E2F1 2 e 3, act as transcriptional 
activators when unbound to RB, one of the pocket proteins with which activator E2Fs 
associate. It is well established role of impairment of E2F/RB pathways in tumor (here 
reported in paragraph 2.2.3). During quiescent phase activator E2Fs are sequestered by 
hypophosphorylated RB resulting in suppression of E2Fs target genes and suppression is 
further strengthen by recruitment of chromatin-modifying factors. On the other hand, growth 
stimuli result in expression of CDKs which phosphorylate RB thus, leading E2Fs in active 
status.  
Given the involvement of activator E2F in mediate M606 downregulation of MYCN, it was 
hypothesized a change in phosphorylation pattern of RB protein. Results show decreased in 
hyperphosphorylated state of RB in two neuroblastoma cell lines BE(2)-C and LAN1 (Figure 
17.A and C). To better understand whether this could be a generalized mechanism common 
to iron chelator drug class, another iron chelator Exjade or EXJ was tested. Results indicates 
that also Exjade induces a decrease in MYCN protein level and favors hypophosphorylated 
RB state. Action of Exj on MYCN promoter both in LAN and in BE(2)-C involves E2Fs 
sites (Figure 17.B and D). 
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Fig.18. Downregulation of MYCN involved dephosphorylation of RB protein. Data are represented as mean of at least 3 
independent experiments ±SEM standard error of the mean. Data were normalized on exon 62 of dystrophin DMD. All 
grey bars represent negative controls.  
A. Western blot analysis on BE(2)-C after 12 hours of 15µM M606 treatment; 
B. Western blot analysis on BE(2)-C after 12 hours of 100µM Exjade treatment on right panel and dual luciferase assay on 
left panel. 
C. Western blot analysis on LAN1 after 12 hours of 15µM M606 treatment; 
D. Western blot analysis on LAN1 after 12 hours of 100µM Exjade treatment on right panel and dual luciferase assay on 
left panel. 
2.7 M606 induces change in expression of RB pathway related genes and 
MYCN/MAX/MXD Network members 
Region of 24 bp upstream of the multiple transcription start site of MYCN promoter 
identified as involved in M606 action is known to mediate responsiveness to TGFb [80]. 
Transforming growth factor b represents a cytokine that causes growth inhibition in many 
lymphoid and epithelial cell types by inducing hypophosphorylation of RB protein. Thus, it 
was hypothesized the involvement of TGFb in mediate RB dephosphorilation. Results 
indicates a strongly increased in p21 (CDKN1A gene) emerged, accordingly with cell cycle 
exit. Moreover, analysis reveals a drug-related alteration of E2F members. Exjade treatment 
in both BE(2)-C and LAN1 results in increased levels of activator E2Fs and E2F7, a 
repressive protein which regulates transcription without association to RB. Same Exjade 
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treatment induce upregulation in all TGF-related mRNA in BE(2)-C including TGFa, 
TGFb1-2-3 and TGF receptors and in LAN1 results in TGFb1-3 and TGF receptors increase. 
M606 action on both BE(2)-C and LAN1 results in TGFb1-2-3 increase and in LAN1 
induces also upregulation of TGF receptors. 
It is known that in the E2F/RB-mediated onset of pathology there could be distinct 
transcriptional mechanisms mediated by deregulated E2F or physiologically activated E2F 
and peculiarity of deregulated E2Fs is the ability to induce transcription of both typical and 
atypical E2F target genes due to dysfunction on the related pathway. Data reveals no 
variation of atypical E2F target gene CDKN1B (p27Kip1) both in LAN1 and BE(2)-C. 
                 
Fig.19. qRT-PCR of RB pathway related genes on BE(2)C (panel A) and LAN1 (panel B) after 15µM and 100µM of 
respectively M606 and Exjade treatment for 12 hours. Data are expressed normalized on untreated samples. White colored 
panels indicate out of range values while cross indicate data excluded from analysis. All data shown as mean of at least 2 
independent experiments ±SEM standard error of the mean. Statistical analysis was performed using one-way analysis of 
variance (ANOVA) with Bonferroni's post hoc test; Internal reference gene used was GlUcuronidaSeBeta, GUSB. 
 
MXD proteins are members of the bHLHz motif network which MYCN belongs to together 
with MAX and MNT. While MNT and MAX appear to be expressed independently from 
cell cycle, MXD expression is confined to differentiated quiescent cells, thus limited to arrest 
and differentiation time points. 
Results on BE(2)-C shows induction of MAX and MXD proteins and in parallel a decrease 
in MYCN protein levels.  
Fig.20. Western blot analysis on BE(2)-C treated for 12 hours with 15µM of M606. Actin was used as internal control.  
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Amplification of MYCN gene is common to many types of infancy cancers of mostly 
neuroendocrine origin, including medulloblastoma, astrocytoma, Wilms' tumor, small cell 
lung cancer, osteosarcoma, rhabdomyosarcoma and about 25% of neuroblastoma (NB) 
[43,44]. Neuroblastoma is an embryonal malignant tumor characterized by deep genetic 
heterogeneity that results in different NB subtypes. A subset of malignant NBs is 
characterized by MYCN oncogene amplification and overexpression that strongly correlate 
with poor prognosis [5]. Weiss et all, revealed that overexpression of MYCN alone was 
sufficient to initiate NB formation in mice [35]. Moreover, no NB has been shown to amplify 
another gene that did not also amplify MYCN and, its protein coding domain is rarely 
mutated making reside its oncogenic properties on regulatory mutations that lead to 
uncontrolled high expression [36,51]. Given these observations, it was suggested that 
inhibition of MYCN expression and/or MYCN-mediated transcription pathways provides 
an attractive therapeutic target for treatment of NB. 
1 Genetic modulation of the MYCN/MAX/MXD network 
MYCN is a member of the MYC gene family and encodes for a transcription factor which 
can regulate approximately 10-15% of the whole genome both directly associated to DNA 
and indirectly via recruitment of other transcription factors already associated to regulatory 
DNA regions [55]. Direct MYCN-related activation of transcription requires 
heterodimerization with its obligatory partner MAX that results in a functional transcription 
factors which can bind E-box sequences located near promoters or enhancers of target genes. 
MAX, together with MYCN, belongs to an extended network of transcription factors defined 
by the presence of a BHLHz motif known to mediate protein-protein interactions among 
members of the network and DNA binding. Role of MAX in modulate MYCN activity 
resides in its ability to both in vitro and in vivo homodimerize and bind E-boxes leading to 
transcriptional repression of MYCN target genes. 
Another level of MAX-mediated MYCN inhibition is MAX availability: among all members 
of the network, MNT is known as the main antagonists of MYCN at first instance, for the 
capability to bind MAX limiting its amount for MYCN binding, but moreover for the 
presence of SIN3 interaction domain (SID) with which can exert its main function as 
repressor of MYCN target genes [116,119,120]. Impairment of the network in cancers are 
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well reported in literature and the role of MAX and MNT in cancer has been widely 
discussed in chapter 2.3 of the introduction.  
All these findings lead to the observation that the sole MYCN amplification can not exactly 
reflect the biological activity of MYCN but its functions are strongly related to the 
expression of MYC/MAX/MXD Network proteins. In the present work, it has been 
highlighted the role of the imbalance in the network in determine the aggravation or the 
improvement of oncogenic cell behaviors. 
Meta-analysis conducts using published gene arrays on Kocak dataset of 649 NB patients 
highlighted that high levels of MAX and MNT in MYCN amplified NB patients are strongly 
related to short term event free probability. On the other hand, emerged that low levels of 
MYCN antagonists in presence of MYCN amplification, are related to good clinical outcome 
[149]. 
In the present work, using RNA interference in MYCN-amplified cells we have 
demonstrated that downregulation of MAX and MNT leads to suppression of the malignant 
phenotype affecting cell proliferation and promoting neuronal differentiation and positive 
prognostic markers and moreover, through transient overexpression, it has been confirmed 
that high levels of MYCN antagonists correlate with improvement of malignant cellular 
phenotype in presence of MYCN amplification.  
 
Modulation of MAX: downregulation of MAX leads to impairment in cell cycle progression. 
MYCN-MAX heterodimer is known to have an important role in transcriptional regulation 
of genes whose products are involved in proliferation [52]. Recent studies have shown that 
upregulation in MAX-MYCN dimer globally elevate the transcription rate of almost all 
genes normally expressed in that specific cellular system [157]. Thus, it is likely that limited 
amount of MAX may be the cause of reduction in proliferation.  
p21Cip1 is a potent cyclin-dependent kinase inhibitor 1 that inhibits CDK2 and CDK1 
complexes mediating cell cycle G1 phase arrest. Many primary neuroblastoma shows p21Cip1 
downmodulation, which is particularly severe in patients with MYCN amplification 
[158].  Moreover, it is known that MYCN-MAX represses the expression of p21CIP1, by 
forming a complex with transcriptional regulators, such as the MIZ-1 and SP1 thereby 
promoting cell growth and cancer onset [62]. Moreover, overexpression of p21Cip1 is related 
to significant neurite extension in neuroblastoma cells [159]. Accordingly with these 
findings, in the present work it has been demonstrated that knockdown of MAX leads to 
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upregulation of p21Cip1 supporting the hypothesis that limited amount of MAX may be the 
cause of modulation of MYCN target genes involved in proliferation and differentiation. 
Neuroblastoma cells retain some features of neural crest progenitors, such as the ability to 
undergo neuronal differentiation in the presence of appropriate signals. When MAX is 
downregulated, BE(2)-C rapidly undergo neuronal differentiation after RA stimuli showing 
most typical morphological changes observed during neuronal differentiation: extensive 
neurite extension, decreased neurite branching, typical neurite alignment and upregulation 
of neuronal marker GAP43.  
The differentiation ability of PC12 cells emphasizes that MAX is not necessary for the 
differentiation process. PC12 are pheochromocytoma cells lacking MAX expression which 
are known to undergo differentiation after stimuli and to induce in vitro transcription of a 
reporter gene linked to the MYC-MAX DNA binding site [107]. The existence of this cell 
line underlines that MYC-MAX complexes may not be absolute requirement for the whole 
MYC function and disruption of MYCN-MAX dimer mitigate malignant phenotype. To 
strengthen this hypothesis, it has been demonstrated that chemical inhibition of MYCN-
MAX dimerization induces cell cycle arrest, differentiation and apoptosis in vitro and 
increased survival in MYCN transgenic mice model [160]. On the other hand, these cells 
fail to upregulate NEFM, the middle-molecular-weight neurofilament protein used as a 
biomarker of neuronal damage and whose down-regulation is a commonly found in 
neurodegenerative diseases as amyotrophic lateral sclerosis, Parkinson's disease, and 
Alzheimer's disease, thus suggesting a neuronal damage despite tendency to differentiate 
into neuronal phenotype [161].  
We have shown that MAX downregulation in MYCN-amplified cell line results in 
expression of TRKA and NGFR with no change in TRKB/BDNF expression. High levels of 
the nerve growth factor receptor TRKA in association with NGFR are considered a positive 
prognostic markers commonly found in favorable NBs, whereas expression of TRKB in 
association with its ligand brain-derived neurotrophic factor BDNF is restricted to malignant 
NBs [29-31]. Moreover, TRKA and NGFR are MYCN negative targets and their expression 
induces differentiation and neurite outgrowth in PC12 pheochromocytoma cell line lacking 
MAX expression [162]. These lines of evidence suggest that limited availability of MAX 
may be the cause of MYCN target genes modulation. 
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Prognostic value of MMP/TIMP ratio in NB help in prediction of clinical outcome and 
define clinical stages. We have demonstrated that MAX knockdown in SK-N-BE(2)-C is 
associated with a shift in balance towards TIMP-2 expression after RA-treatment. Ratio 
between metalloproteinase MMP-2 and its inhibitor TIMP-2 is responsible for extracellular 
matrix proteolysis and degradation. Increased expression in NBs of MMP-2 in association 
with low levels of TIMP-2 is associated with poor clinical outcome and advanced clinical 
stages [152]. 
MMP-9 seems not to be associated with NB clinical stage and prognosis although it is well 
established its role in differentiation of adult neural progenitor cells. Experimental data 
reinforcing this evidence highlights association between MMP-9 expression in SK-N-BE 
after RA treatment and phenotypic neuronal-like differentiation. Moreover, MMP-9 
knockdown promotes tumor invasion in mouse model of MYC-induced pancreatic 
neuroendocrine tumors [152-155]. In line with these findings, it has been here reported that 
knockdown of MAX induces increased expression of MMP-9 and RA induction of 
differentiation can enhance this expression.  
It is well known the role of MYCN expression in promoting cellular migration of 
neuroblastoma cells and moreover it has been highlighted that enhanced migration is 
proportional to MYCN levels [163,164]. We have demonstrated that MAX knockdown 
results in impairment of migratory capability. According to clinical data, here it has been 
demonstrated that silencing of MAX in presence of MYCN amplification results in reduced 
aggressive phenotype and lines of evidence suggest that main effects are related to limitation 
in the availability of MAX. 
On the other hand, accordingly to clinical Kocak dataset, MAX overexpression enhances 
cancerous features of BE(2)-C. As previously mentioned, BE(2)-C are highly malignant 
MYCN amplified cell type and worsening its cancerous phenotype grade is a hard effort. 
Alternate mRNA splicing produces two major highly conserved MAX isoforms, the longer 
of which MAXL differs from the shorter form MAXS for an insertion of 9-amino acid at 
codon11. Both proteins are expressed at approximately equal levels in most cell types but 
evidence suggests that MAXL can bind DNA more strongly than MAXS and that MAXL is 
able to repress a MYC-responsive reporter gene whereas MAXS had little effect on its 
expression but rather stimulated its expression.  Furthermore, cells overexpressing MAXS 
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and not ones overexpressing MAXL do not shows variation in growth rate and accelerated 
apoptosis after growth factor depletion, suggesting its protective role [115].  
In the present work we confirm that MAXL and not MAXS overexpression in BE(2)-C 
results in increased proliferation rate through downregulation of p21 Cip1. Moreover, MAXL 
overexpression leads to a slightly decrease in neurite formation after RA treatment without 
affecting expression of positive prognostic markers but rather inducing TRKB, a negative 
prognostic marker found in unfavorable NBs [165,166]. 
MAXL overexpressing cells shows also a slightly increase in motility. It is known that 
coexpression of MAXL with cMYC has a stimulatory effect due to its predilection to 
heterodimerize [115]. Our evidences confirm the stimulatory action of MAXL and not 
MAXS in worsening of the malignant phenotype of neuroblastoma cells.  
Moreover, here we shown that overexpression of MAXS results in no modulation of neither 
proliferation nor migration but rather upregulation of positive prognostic markers TRKA 
and NGFR and upregulation of neuronal differentiation markers GAP43 and NEFM, 
strengthening the hypothesis of the protective MAXS role compared to MAXL [115,167]. 
MAXL and MAXS are the major isoforms of this protein and how they differ functionally 
from one another has not been determined. Accordingly, to literature, we have shown that 
two isoforms regulate gene expression, cell cycle progression, motility and differentiation 
in different ways. This could be probably due to a different pattern of CKII phosphorylation, 
which moreover, is known to affect MAX binding to DNA and regulate association with 
MXD proteins, although further experiments need to be done to fully explain their different 
biological behaviors [167].  
Modulation of MNT: downregulation of MNT leads to impairment in growth rate not strictly 
dependent to upregulation of p21Cip1. Whereas MYCN-MAX are known to actively 
promotes transcription through recruitment of coactivators thus inhibition leads to absence 
of dimer formation, MAX-MNT repress transcription through recruitment of mSin3 
corepressor and involvement of deacetylases [116-120]. As a consequence, it is expected 
that MNT loss results in worsening of cancerous phenotype but it was not.  
Role of MNT in apoptosis emerges from experiments highlighting the lethal effect of 
combined MNT loss and MYC overexpression in T cells and MEFs also associated with 
high levels of ROS production that, when accumulated beyond thresholds could be toxic and 
induce apoptosis. [117,169].  Thus, inhibition of malignant phenotype mediated by MAX-
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downregulation may be due to lack in MYCN-MAX dimer formation, whereas loss of MNT 
may probably activate apoptotic pathways. 
MNT knock down cells exhibit expression of TRKB in absence of BDNF. Coexpression of 
bone derived neurotrophic factor receptor and its ligand are negative prognostic markers in 
NBs associated with poor prognosis, and providing invasive and metastatic capability and 
enhancing therapy resistance [29-31] On the other hand, many studies underline the role of 
the sole TRKB expression in neurite formation thus suggesting its putative role in neuronal 
differentiation [165-166]. Accordingly, MNT-KD cells show strong upregulation of 
neuronal marker GAP43 and furthermore, RA induction results in increased levels of MMP-
9 that is known to be associated with phenotypic neuronal-like differentiation, accordingly 
to what found for MAX-KD cells [152-153]. However, these cells do not develop any neurtic 
process, suggesting the requirement of MNT protein to complete differentiation process.  
MNT knock down cells exhibit expression of positive prognostic markers TRKA and NGFR 
and a balance in MMP/TIMP that favors TIMP-2 expression after RA treatment.  
The importance of MNT also emerges from its constant expression regardless of the cell 
cycle or the proliferative status. Indeed, these cells fail to upregulate NEFM, leading to 
suggest a neuronal damage in agreement with activation of apoptotic pathways [150]. Seems 
likely that MAX-MNT or MLX-MNT affinity and DNA binding could not be identical, thus 
phenotype observed after partially depletion of MNT could be a result in unbalance between 
formation of these dimers [168].  
We have demonstrated correlation between good clinical prognosis in presence of MNT loss 
and cellular model of MNT knockdown. 
On the other hand, overexpression of MNT results in enhanced malignant phenotype of 
BE(2)-C with strongly effect on proliferation rate through downregulation of p21 Cip, low 
levels of differentiation and positive prognostic markers TRKA and NGFR and moreover 
upregulation of TRKB expression, commonly found in unfavorable NBs. A slight 
enhancement in migratory capability is also observed.  
MNT is known to mediate the repressive side also of the MONDO-MLX pathway, thus it is 
possible to ascribe the resulting phenotype even to an impairment in this side of the network.  
Through MNT ChIP-Seq data from ENCODE it was highlighted the presence of a subsets 
of MNT target genes that may not overlap with MYC-MAX target genes and whose action 
is still to investigate [168]. MNT is known to interact with Sin3 to induce transcriptional 
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repression and deletion of SID domain converts MNT from repressor to activator [171]. 
Given repressive effect of MNT mediated by mSin3 and given also mSin3 limited amount 
within cells, it is likely that effects of MNT upregulation may be probably linked to the 
presence of these subsets of genes.  
Interestingly, MYC and MNT levels appear to autoregulate through a feedback system in 
which ectopic MYC expression induces endogenous expression of MNT and absence of 
MNT decrease MYC levels as a needed to counteract MYC excessive apoptosis both 
normally and in the context of tumorigenesis [169,170]. OX40 receptor activated T cells 
have a very robust proliferative response associated with both induction of MYC, MNT and 
MXD4 that appear to have main function in limiting apoptosis sustaining T cell proliferation 
[170]. Moreover, MNT and MXD4 are known to decreased during nerula stage in Xenopus, 
immediately before neural tube development, stages in which MYCN expression together 
with other necessary factors, is essential in migrating neural crest cells for the rapid 
expansion of progenitor population and then decrease during neural differentiation [76,172]. 
Fully explanation of the mechanisms underlying worsening of cell phenotype after MNT 
upregulation in MYCN amplified condition need further elucidation that, to date, are still 
lacking. Whereas a huge amount of literature exists on the role of imbalance in network 
members in physiological conditions, but less is known about impairment of the network in 
MYC or MYCN amplified conditions. Canonical scheme of MNT as a main MYCN 
antagonist should be probably revaluated in light of this unexpected role of MNT. Different 
independent studies underline that loss of MNT both via deletion or inactivation is not 
selective for oncogenesis as expected but may even be detrimental and selected against 
[117,118,168]. 
2 Pharmacological modulation of the MYCN/MAX/MXD network 
To date, current treatment for NB consists of surgery, chemotherapy, radiation, and 
biotherapy but the main treatment for NB is based on chemotherapy combining different 
cytotoxic drugs that often has MYCN as molecular target [132,133]. The rationale for choose 
MYCN as a therapeutic target for treatment of NBs lies firstly in its deregulated expression 
commonly found in malignant tumors and associated with poor patient outcome. 
Furthermore, it has a restricted expression related to the early stages of embryonic 
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development and virtually undetectable in normal post-natal tissues. Despite the 
attractiveness of MYCN as a therapeutic target and the discovery of new MYCN targeting 
compounds, most of them have not passed the pre-clinical stage because of their non-
specificity or selection of resistant clones. The main molecular class of cytotoxic compound 
used affecting MYCN expression is iron chelator [132,133] Epidemiologic studies on higher 
cancer incidence in iron overload individuals have pointed out the role of iron in cancer and 
many clinical trial are going on testing new iron chelator compounds to treat high risk NBs 
[130,131]. 
In the present work, it has been identified the molecular pathways of MYCN downregulation 
induced by M606, a novel iron chelator compound derivative of hydroxyquinolones. M606 
can strongly induces MYCN protein and mRNA downregulation without affecting stability 
but rather acting at transcriptional level. 
Combined IFN-g and retinoic acid therapy correlates also with decrease in acetylation, 
indicative of a chromatin in a transcriptionally repressed state [173]. Here we demonstrate 
that M606-induced MYCN downregulation occurs through decrease in chromatin 
acetylation and not methylation pattern. 
Moreover, M606 action on MYCN protein is related only to actively proliferating cells. 
Many cancer chemotherapy agents are known to selectively kill actively dividing cells (sub-
confluent cell cultures) rather than sparing cells that are not dividing [174]. 
In the present work, it has been shown that E2F1 and E2F2 consensus have been found 
necessary to induce M606 impairment of MYCN promoter driven transcription of a reporter 
gene. E2Fs sites on MYCN promoter are upstream of the multiple transcription start site, a 
region highly conserved in the human and mouse MYC genes and mediate major part of 
promoter activity and responsiveness to TGFb and comprises three E2F sites, two of which 
are inversely oriented and overlapped and one TIE TGFb inhibitory element was identified 
[80]. 
Strieder et al. demonstrates the binding of E2F1, 2 and E2F3 to the 
proximal MYCN promoter in vivo and that inhibition of E2F activity in through 
overexpression of p16INK4A induced a reduction MYCN expression [80]. 
E2F/Rb pathway is essential for modulation of cell cycle, differentiation and survival of 
various cell types in the developing and adult CNS [94-96]. Although neither RB gene 
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mutations nor any other protein mutations known to inactivate the pRb pathway in other 
types of tumors have been detected in NBs, recent evidence suggests that E2F/Rb activity in 
NBs may be deregulated [81]. pRb pathway is found deregulated in many human cancers 
and neurodegenerative diseases such as Alzheimer, Parkinson’s disease and Amyotrophic 
lateral sclerosis show active E2F and aberrant or hyperphosphorylated RB expression 
resulting in increased expression of E2F target genes [88-90]. The regulatory essence of E2F 
activator complexes is based on the ability to interact with pocket proteins but also to bind 
DNA with high affinity. Association of hypophosphorylated Rb to activator E2Fs sequesters 
their transactivation domain responsible for transcription of target genes and furthermore 
induces recruitment of chromatin remodeling complexes (e.g. HDAC), whereas 
hyperphophorylated RB are unable to interact with liberating their transactivation domain 
and allowing transcription of E2F target genes [81]. 
In the present work, it was pointed out that M606 can induce hypophosphorylated status of 
RB supporting the hypothesis of RB sequestration of E2F transactivation domain, thus 
resulting in E2F target gene downregulation. Here, it has been demonstrated that also Exjade, 
another iron chelator can act through the same mechanisms leading to hypothesize the 
presence of a generalized iron chelator mechanism that act via RB dephosphorylation. 
It is known that in the E2F/RB-mediated onset of pathology there could be distinct 
transcriptional mechanisms mediated by deregulated E2F or physiologically activated E2F 
and peculiarity of deregulated E2Fs is the ability to induce transcription of both typical and 
atypical E2F target genes due to dysfunction on the related pathway [87]. In the present 
work, it has been demonstrated that both Exjade and M606 fail to modulate the atypical E2F 
target gene p27Kip1 thus suggesting a physiologically activation of E2F released from RB.  
The cyclin-dependent kinase inhibitor p21Cip1 mediates cell cycle G1 phase arrest and is 
related to significant neurite extension in neuroblastoma cells [159]. Moreover, it is known 
that MYCN-MAX represses the expression of p21CIP1, by forming a complex with 
transcriptional regulators, such as the MIZ-1 and SP1 thereby promoting cell growth and 
cancer onset [62]. p21Cip1 have been shown to be upregulated after M606 treatment. 
There is also evidence that E2F proteins are involved in the negative regulation 
of MYCN induced by TGFβ and the 24bp identified region is known to mediate 
responsiveness to TGFb [80]. Via qRT-PCR it has been shown upregulation of TGFb  and 
TGF receptor in both BE(2)-C and LAN1 suggesting an autocrine pathway of autoinhibition 
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that need further to be fully clarified. Exjade treatment also induces modulation of E2F 
protein family, contrary to M606. This could be probably due to their different iron 
capability or molecular structure.  
Combined treatment with IFN-g and retinoic acid is known to induce MYCN 
downregulation but further upregulation of MXD protein that is known to be associated with 
differentiation cellular phenotype [173]. MXD proteins are members of the bHLHz motif 
network which MYCN belongs to together with MAX and MNT. While MNT and MAX 
appear to be expressed independently from cell cycle, MXD expression is confined to 
differentiated quiescent cells, thus limited to arrest and differentiation time points. 
Accordingly with these findings, we demonstrate that M606 induce expression of MXD1 
and MAX in SK-N-BE cells in presence of low levels of MYCN protein. 
3 Final Remarks  
Overall these studies provide evidence supporting the hypothesis that it is not the unique 
MYCN amplification that reflect the biological activity of MYCN but rather this is strongly 
related to the expression of MYCN/MAX/MAD network proteins. Overall, our results fully 
mimic the clinical condition in which a direct correlation between downregulation of MAX 
and MNT and good prognosis in MYCN amplified NB patients is observed. We have 
demonstrated that: 
• knockdown of MAX leads to suppression of the malignant phenotype affecting cell 
proliferation, promoting neuronal differentiation and enhanced expression of 
differentiation and positive prognostic markers in MYCN amplified cell line; 
• knockdown and MNT leads to attenuation of the malignant phenotype inducing 
decrease in cell proliferation and enhanced expression of differentiation and positive 
prognostic markers in MYCN amplified cell line. 
 
We further demonstrate correlation between high levels of MAX and MNT protein in 
MYCN amplified context and poor prognosis accordingly to clinical data in which 
expression of MYCN counterparts is related to short therm survival: 
 
Discussion 
 
 75 
• high levels of MYCN antagonists correlate with improvement of malignant cellular 
phenotype in presence of MYCN amplification affecting proliferation, migration and 
inducing expression of negative prognostic markers and repression of positive ones 
 
Our study reveal also a dualism between two MAX long and short isoforms highlighting that 
they differentially regulate gene expression, cell cycle progression, motility and 
differentiation in different way. Our evidences confirm the stimulatory action of MAXL and 
not MAXS in worsening of the malignant phenotype of neuroblastoma cells and point out 
basis for further study on two MAX isoforms and their expression pattern in low and high 
risk NBs. 
In the second part of the present work, a novel compound named M606 was characterized 
for its ability to repress MYCN at transcriptional level. Its action on MYCN promoter 
involved 24 bp upstream of the multiple cloning site of MYCN promoter and activator E2F 
consensus seems to be necessary.  
 
 
 
Schematic representation of the hypothesized mechanism of M606 action proposed for the downregulation of 
MYCN. 
 
Here it is hypothesized the mechanism of action involved in MYCN downregulation 
mediated by two iron chelators: iron chelation through both Exjade and M606 treatment 
induces upregulation of CDK inhibitors and results in hypophosphorylated status of RB 
protein that can bind activator E2Fs and sequester their transactivation domain. Repression 
of MYCN promoter is strengthen to the further recruitment of chromatin remodeling 
complexes. 
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Our findings provide evidence for deregulated E2F/RB pathways in NBs supporting the 
hypothesis of presence of physiologically activated E2Fs and not deregulated ones. 
In conclusion, we have partially elucidated the molecular pathways through which a novel 
iron chelator mediates MYCN downregulation. 
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NEUROBLASTOMA CELL CULTURES  
Human neuroblastoma SK-N-BE(2)-C and LAN1 cell lines were maintained and cultured 
in high glucose DMEM containing 10% of fetal bovine serum, L-glutamine 2mM, 
Penicillin–Streptomycin solution with penicillin 100 U/mL of penicillin and 100 µg/mL 
streptomycin in a humidified atmosphere of 5% CO2 at 37 °C. 
DRUGS AND REAGENTS  
When indicated, cells were treated with 15µM of M606, 100µM of Exjade or in 
combination with FeSO4 15µM for 12hours, or in combination with 15µM of Panobinostat 
(Aurogene). Drugs were resuspendend in DMSO and stored at -80°C, whereas Iron was 
freshly prepared for each experiment. M606 was kindly provide by research group of Dr. 
Michelle Haber from Children’s Cancer Institute, Australia, Sidney. All trans-Retinoic acid 
(Sigma-Aldrich) is resuspended in DMSO and used at 10µM of final concentration. 
RNA EXTRACTION  
The procedure is described for two 100mm dishes of cultured cells at 70% of confluence. 
Same procedure is adopted for M606 experiments with cultured cells grown in five 100mm 
dishes at 20-30% of density. Sigma-Aldrich TriReagent protocol is adopted. Remove 
medium and rinse dishes with 1mL of PBS1X. Add 1mL of trypsin-EDTA 0,05% to plate 
to detach cells and neutralize trypsin action with 5mL of DMEM and transfer the 
suspension in a 15mL tube. Centrifuge 5m 1000rpm and remove supernatant. Add 1mL of 
TriRiagent to the pellet, gently mix and incubate for 5min at RT. Add 200 µL of 
chloroform and vortex. Incubate for 5min at RT. Centrifuge 5m 12000rpm at 4°C and 
transfer aqueous phase into a new tube containing 500 µL of isopropyl alcohol and vortex. 
Incubate for 5min at RT. Centrifuge 15min 12000rpm at 4°C and remove supernatant. 
Wash twice pellet with 1mL of EtOH 75% diluted in DEPC treated water. Centrifuge 
10min 12000rpm at 4°C and remove supernatant and let the pellet dry. Resuspend it in 50 
µL of water treated with DEPC and heat sample 10min at 55°C. 
DNase I TREATMENT 
After quantification of RNA by spectrophotometric analysis to verify quality (ratio 
260/280 > 1.8, ration 260/230 > 1.7), DNase treatment is necessary to digest the 
contaminant genomic DNA. DNase treatment of 1,5 µgr of RNA is performed using the 
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DNA-free kit (Ambion, Life Technologies), with 0,75 U of rDNase I in 15 µL of final 
volume. Mix is incubated for 30min at 37°C and that DNase is inactivated using 0.1 
volume of Inactivation Reagent. Incubate 2min RT, mixing occasionally.  Centrifuge 2min 
10000rpm RT and transfer RNA in a fresh tube. 
REVERSE TRANSCRIPTASE REACTION  
The RT-PCR was designed for the reproducible and sensitive detection and analysis of 
RNA molecules in a two-step process. Avian reverse transcriptase RT (Bio-Rad) with 
reduced RNase H activity, was engineered to have higher thermal stability and to produce 
higher yields of full-length cDNA. Reverse transcription is performed using iScript 
Reverse Transcription Supermix (Bio-Rad). 5x ready to use cocktail contains MMLV 
RT(RNAseH+), RNAse inhibitor, random hexamers and oligo-dTs, buffer, MgCl2, dNTPs, 
buffer and stabilizers. Reverse transcription is performed on 1 µgr of RNA in 20 µL of 
final volume. Thermal cycler setting provided by BioRad is as follow: priming for 5min at 
25°C, Reverse Transcription for 30min at 42°C and inactivation at 85°C for 5 min. Add the 
appropriate water volume up to 100 µL and store at -20°C or use for qPCR immediately.  
REAL TIME QUANTITATIVE PCR 
SsoAdvanced Universal SYBR Green (BioRad) for ICycler CFX96 is used in the 
quantitative real time PCR. SYBR Green I dye is an asymmetrical cyanine dye for dsDNA 
stain resulting in DNA-dye complexes that absorb light at 497 nm, and emit fluorescence 
at 520 nm recorded, in our condition, after annealing and elongation steps. 
It is a 2X ready to use mix with all components, except template and primers: 1µM of 
Fluorescein Reference Dye, enhancers, dNTPs, MgCl2, polymerase, SYBR Green I dye 
and stabilizers. For multiple reactions, master mix is prepared and after adding the 
appropriate master mix volume to each tube, the unique reaction components are added. 
Forward and reverse primers are used at final concentration of 200nM. 20ngr of template 
are used. The TaqDNA polymerase provided in the SuperMix has been chemically 
modified to block polymerase activity at RT, allowing room-temperature reaction setting 
up and long term storage at 4°C. Activity is restored after a 10-minutes incubation in PCR 
cycling. Protocol used in ICycler CFX96 for qPCR is as follows: polymerase activation 
and DNA denaturation for 30sec 95°C, 40 cycles of denaturation for 15sec at 95°C and 
elongation for 30sec at 60°C. Melting curve analysis is the final step characterized by an 
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increment of 0.5°C 2-5 sec/step of the temperature from 65°C to 95°C. Primer used in 
qPCR are listed below: 
NAME	 SEQUENCE	FOREWARD		 SEQUENCE	REVERSE	
MYCN_qRT-PCR	 GATGCACCCCCACAGAAGAA	 CTCCGAGTCAGAGTTTCGGG	
GUSB_qRT-PCR	 AGCCTGGAGCAAGACAGTGG	 ATACAGATAGGCAGGGCGTTCG	
CDKN1A(p21)	_qRT-PCR		 ATTAGCAGCGGAACAAGGA	 CAACGTTAGTGCCAGGAA	
MAX_qRT-PCR		 GAAGGGGAGGGGGAAGTC	 CCGTGTTGTGTGTGTGTGTG	
MNT_qRT-PCR		 CAGGAGGGCCCATCTGAAAG	 CCTTCCTCTTCAGGGACTGGA	
TRKA_qRT-PCR		 TCAACAACGGCAACTACACG	 TGAACTCGAAAGGGTTGTCC	
TRKB_qRT-PCR		 GGGACACCACGAACAGAAGT	 CACCACAGCATAGACCGAGA		
NEFM_qRT-PCR		 TCAGCGGCTCCCCGTCCAGT	 TCTCGGCGGAGCTGAGCATGG	
GAP43_qRT-PCR		 AGGGAACCTGGTCTCTGGGTTGT	 TCGTCACCCAGGTGATGCTGTGA	
TIMP2_qRT-PCR		 GTTCAAAGGGCCTGAGAAGGA	 CGGCCTTTCCTGCAATGAGA	
MMP2_qRT-PCR		 TGATGGCATCGCTCAGATCC	 GGCCTCGTATACCGCATCAA	
MMP9_qRT-PCR		 CTTTGAGTCCGGTGGACGAT		 TCGCCAGTACTTCCCATCCT	
BDNF_qRT-PCR		 TCAAGCCTCTTGAACCTGCC	 TGCCCCCATGAAAGAAGCAA	
E2F1_qRT-PCR		 TCGTAGCATTGCAGACCCTG	 TGAAAGTTCTCCGAAGAGTCCA	
E2F2_qRT-PCR		 CAACATCCAGTGGGTAGGCA	 TGCTCCGTGTTCATCAGCTC	
E2F3_qRT-PCR		 GTTGTGAAAGCCCCTCCAGA	 AATGGGCCCTTGGGTACTTG	
E2F4_qRT-PCR		 ACCCCACAGGTGTTTTGGAA	 GGGGCAAACACTTCTGAGGA	
E2F5_qRT-PCR		 TCTTCAGCAGGATCTATTAGTGG	 TGTAGTCATCTGCCGGGGTA	
E2F6_qRT-PCR		 ATAAGGAGCACCAACGGACC	 TCCCGACACCTTCAGACCTT	
E2F7_qRT-PCR		 CAGGCAGCCCAGACTAGATT	 TCTTCGGGGCCATCCTTGAT	
E2F8_qRT-PCR		 ATCCCAACCCTGTGTGAAT	 CGAAATGCGTCGACGTTCA	
TGFa_qRT-PCR		 GCCCAGATTCCCACACTCAG	 ACGTACCCAGAATGGCAGAC	
TGFb_qRT-PCR		 GGAAATTGAGGGCTTTCGCC	 AGTGAACCCGTTGATGTCCA	
TGFb2_qRT-PCR		 AAGAAGCGTGCTTTGGATGC	 AAAGTGGACGTAGGCAGCAA	
TGFb3_qRT-PCR		 CCCAGCTCTAAGCGGAATGA	 TAGCGCTGTTTGGCAATGTG	
RB1_qRT-PCR	 GCCTCTCGTCAGGCTTGAGT	 CCAAGCTCTCTCTCTGACATGA	
RBL1_qRT-PCR	 TCTAACAATGGCCACAGCCC	 GCATCATTTGCGACACCATGT	
RBL2_qRT-PCR	 AGAGGAGAGGGGAGACCTCA	 GGGAGAGAGTGGAGGAGCAT	
TGFb1R_qRT-PCR	 GGTTCCGTGAGGCAGAGATT	 CACCAACCAGAGCTGAGTCC	
TGFB2R_qRT-PCR	 GCAGCATCACCTCCATCTGT	 TTGGGGTCATGGCAAACTGT	
SMAD2_qRT-PCR	 TGGGGACTGAGTACACCAAA	 ACGACCATCAAGAGACCTGG	
SMAD3_qRT-PCR	 TGCAAGATCCCACCAGGATG	 GGGTCAACTGGTAGACAGCC	
SMAD4_qRT-PCR	 CCAATCATCCTGCTCCTGAGT	 TAGGGCAGCTTGAAGGAACC	
CDKN2A(p14)	_qRT-PCR		 GTTTTCGTGGTTCACATCCCG	 CATCATGACCTGGTCTTCTAGG	
CDKN1B(p27)	_qRT-PCR		 TAATTGGGGCTCCGGCTAAC	 GAAGAATCGTCGGTTGCAGGT	
 
TOTAL AND NUCLEAR PROTEIN ISOLATION  
First step is common to both protocols: remove medium and rinse dishes with 1mL of 
PBS1X. Detach cells from the plate adding 1mL of trypsin-EDTA 0,05% to plate and 
neutralize trypsin action with 5mL of DMEM and transfer the suspension in a 15mL tube. 
Centrifuge 5m 1000rpm and remove supernatant. 
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The procedure is for the total protein extraction is described for 1100mm dishes of cultured 
cells at 70% of confluence. Same procedure is adopted for M606 experiments with 
cultured cells grown in five 100mm dishes at 20-30% of density. Resuspend pellet into 
about 100 µL of ice-cold RIPA buffer. Vortex and incubate in ice for 15min. Sonicate for 
10min at maximum intensity. Centrifuge 20min 13000rpm at 4°C and transfer the 
supernatant to a new tube. Store at -80°C. 
The procedure for the nucleic protein extraction is described for two 100mm dishes of 
cultured cells at 70% of confluence. Same procedure is adopted for M606 experiments 
with cultured cells grown in five 100mm dishes at 20-30% of density. Resuspend pellet 
into 500 µL of hypotonic solution. Centrifuge 5min 1500rpm at 4°C and again resuspend 
pellet in 500 µL of hypotonic solution let tube incubate for 15min in ice. Add 500 µL of 
hypotonic solution + NP40 0,4% (final concentration of 0,2%) and let tube incubate for 
15min in ice (10min for LAN1). Centrifuge 10min 6000rpm and resuspend nuclei in high 
salt solution. Rotate the sample 1hour in cold room vortexing every 10min. Centrifuge 
15min 13000rpm at 4°C. transfer supernatant in a fresh tube and quantify it.  
Note: M606 experiment were performed using variation of high salt solution listed below. 
                      
Quantification is performed using BCA methods (ThermoScientific) with standard protocol 
supplied by company. 
 WESTERN BLOT ANALYSIS AND ANTIBODIES 
Protein mixes obtained by nuclear or total extraction were separated by SDS-PAGE in 
10% or 12% poly-acrylamide gels. 
Materials and methods 
 81 
    
50-100 µgr of nuclear extracts or 30-50 µgr of total extracts were loaded. 
Running buffer: tris 25mM, glycine 190mM, SDS 0,1% pH 8.3 
Transfer buffer: tris 25mM, glycine 190mM, Methanol 20% pH 8.3 
Blocking solution: NaCl 150mM, TrisHCl 20mM pH 8, Dried Milk 4% 
 
All antibodies were purchased from Santa-Cruz: MNT (sc-769); Actin (sc-1616); MAX 
(sc-197); MYCN (sc-53993); RB (sc-50); pRBSer608 (sc-56174). Antibody FLAG M2 
(F3165) was purchased from Sigma. 
ShRNA PRODUCTION AND SILENCING ASSAYS 
Briefly, packaging cells chosen for viral production were HEK 293T. cells were 
transfected using Effectene kit (QUIAGEN) with packaging vectors from Addgene: 
pMD2.G (#12259), psPAX2 (#12260) and pLKO.1 TRC ShRNA backbone plasmids. 
pLKO.1 Lentiviral Scramble shRNA (#RHS6848) and pLKO.1 Lentiviral MAX 
(#RHS3986) and MNT (#RHS2039) were purchased at Open Biosystems-GE Dharmacon.  
Optimization experiment was carried out using puromycin dose response or kill curve and 
testing various Multiplicity of infection (MOI). For shRNA experiments, SK-N-BE(2)-C 
cells were transduced for 12 hours with MOI 10 and polybrene concentration at 10µg/ml, 
following selection with 50 mg/ml puromycin. 
DAY 1: plate 6x10^6 HEK 293T 
DAY 2: Prepare the following mix x each sample: 100 µL Buffer EC, 0.5 µgr psPAX2, 1 
µgr pMD2.G. Vortex and add the specific pLKO.1 plus 4 µL enhancer solution. Vortex 
and incubate RT 15min. Add Effectene 16 µL and incubate for 30 min RT. During the 
incubation, change medium to the 293T cells plated the day before with 1 mL of fresh 
medium and then add to the cells. Virus production will start after about 12 hours. 
DAY 3: After 12 hours from transfection, change medium to 293T to collect virus in a 
fresh medium. Prepare the cells will be infected (BE(2)-C). Plate 3x10^6 cells in a 6 well 
dished. 
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DAY 4: filter the supernatant using a 0.45 µm filter, use it or store at - 80°C until use. 
INFECTION: Some cells as primary cells are sensitive to Polybrene, thus determine the 
suitable concentration of Polybrene is recommended. Aspirate the medium and infect cells 
with 250 to 500 µl viral supernatant. Add fresh medium to a final volume of 500 µL 
adding 5 µL of 1 µg/µl Polybrene. 
DAY 5: change medium with fresh DMEM and puromycin 1µgr/mL. It is recommended to 
perform a puromycin kill dose before experiments. 
TRANSIENT TRANSFECTIONS 
BE Tet-Off cells were obtained after transfection of SK-N-BE(2)-C with Tet-Off 
Advanced transactivator plasmid that is a modified transactivator protein optimized for 
expression in mammalian cells. The inducible promoter, PTight, provides low basal 
expression and is tightly controlled by induction with tetracycline. After transfection of 
BE(2)-C using Lipofectamine® 2000 (Life Technologies), single clone were selected 
adding G418 to 0.5 mg/ml. single clones were tested for their ability to induce tetracycline 
response using Dual Luciferase assay and transfecting selected clones with a construct 
carrying Luciferase construct under a tetracycline responsive promoter  (pTRE-Tight-Luc). 
Selected clone was transfected with pTRE3G_MAXL3xFLAG, pTRE3G_MAXS3xFLAG 
and pTRE3G_MNT3xFLAG. Experiments were conduct also on empty vector alone. To 
insert 3xFlag in frame with CDS, selected genes were firstly cloned into pCMV14 and then 
into pTRE3G. MNT(NM_020310.2), MAXL(NM_002382.4) and MAXS(NM_145112.2) 
were cloned. 
Listed below, primers used: 
NAME	 SEQUENCE	FOREWARD		 SEQUENCE	REVERSE	
MNT_pTRE3G	 TTTAGATCTATGAGCATAGAGACGCTACTGG	 TTTCATATGCTTGTCATCGTCATCCTTGTAG	
MAX_pTRE3G	 TTTAGATCTATGCAGCGATAACGATGACATC	 TTTGCTAGCGGATCACTACTTGTCAT	
MNT_pCMV14	 AAAAGCTTATGAGCATAGAGACGCTACTGGAGG	 AAGGATCCAGCCAGCTTGAGTGTGCTGAC	
MAXL_pCMV14	 TTTAAGCTTATGAGCGATAACGATGACATCGAG		 TTTGGATCCGCTGGCCTCCATCCG		
MAXS_pCMV14	 TTTAAGCTTATGAGCGATAACGATGACATCGAG		 TTTGGATCCGCTGGCCTCCATCCG		
 
CELLULAR ASSAY 
Wound closure assay was performed to evaluate cells migration. Cells were plated and 
when 70% of confluence were reached, a tip was used to remove a part of cell layer from 
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different separate areas of the growth substrate. To allow stabilization of cells, let them 
stay for 15min and then replace medium to remove debris and start wound closure assay 
photographing areas at regular time points. Final wound size was the result of average of 3 
independent experiments. Analysis were performed using ImageJ. 
 
To evaluate cell proliferation, 300.000 cells were plated in 6-well plate and every day cells 
were counted using trypan blue exclusion method and Nucleocassette from Chemometec. 
The growth curve was results of average of at least three independent experiments.  
 
To evaluate neurite outgrowth, 3 × 10^4 cells were plated onto a 100mm dish in DMEM 
with 0,1% FBS for 48h. Medium was then replaced with complete DMEM with 10% FBS 
and differentiation was induced adding every day retinoic acid ATRA 10 µM for 6 days in 
half fresh medium and half conditioned medium. Photographs of different areas of the 
cultures were taken every day with a phase-contrast microscope. Neurite outgrowth, 
number of cells, and number of neurites was measured using the image analysis software 
ImageJ. Were scored as positive cells with neuritic extensions at least twice the cell body. 
LUCIFERASE ASSAY 
The DLR Dual-Luciferase® Reporter Assay System from Promega, gives an efficient 
means of performing dual-reporter assays. The term “dual” refers to the sequential 
detection of the activities of two luciferases: firefly from Photinus pyralis and Renilla 
from Renilla reniformis. Renilla luciferase-expressing vector is used as internal 
calibrator of the system due to its constitutively basal expression. Firefly vector carries 
promoter sequence of interest. Firefly activity is misured adding LAR II reagent and after 
quantification, the addition of Stop & Glo® reagent to the same tube allow quenching of 
firefly signal and detection of Renilla activity. 
Briefly, 1x10^6 neuroblastoma cells were plated in 24 well plate. The day after, cells 
were transfected using LTX (Life Technologies), and protocol provided by companies.  
NOTE: for BE(2)-C 1.2 µL of LTX was used; for LAN1 1.8 µL of LTX was used in the 
same final volume. 
For M606 experiments on MYCN promoter, different time points were tested and 12 
hours after transfection were chosen. At the selected time point, add 100 µL of passive 
lysis buffer and mix for 20min at RT. Samples are ready to be measured or be stored at -
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80°C. Dispense 30 µL of LAR II into the luminometer tubes then add 20 µL of sample 
and read the luminescence. Then add 30 µL of Stop & Glo Reagent and mix briefly by 
pipetting and read the renilla signal. Data are expressed in RLU or Relative Light Units, 
an arbitrary unit to define firefly activity on renilla activity. 
NAME	 SEQUENCE	FOREWARD		 SEQUENCE	REVERSE	
MYCNp_-1385;1504	 AAAAAGCTTTCACAGCCTGCGCTTTGAAG	 AAACTCGAGGCTGTTCCTGGCTGCAGAAT	
MYCNp_-1385;-2	 AAAAAGCTTTCACAGCCTGCGCTTTGAAG	 TTTGCTAGCGGATCACTACTTGTCAT	
MYCNp_-2;1504	 AAACTCGAGAAAGGACAGGATGCTAGGCG	 AAAAAGCTTGCTGTTCCTGGCTGCAGAAT	
D1 AGATCTCGAGCCCGGGCTAG	 CGTGGTCATCATCATAATAATAGCTGAC	
D2	 CGCCACCATCAAATCCTGGCTTTAC	 CAGCAGCTTTCCTTTTTCCCTTCAAC	
D3	 GAAATGGAGTTCGTAGTGCCTCCTA	 TTAACTTGGGAGCCCTGGGG 
D4	 CAGGCGAATCTGATTTACCGAGATGG	 GCAGCTCCGCTTTCTGCTCA	
D5 GACTGTCCACGCGTCCTCAC	 CCAGAGGTCTTGTTCCTAAGGGGG		
D6 AAATAAATAAGTGCGAGCTACGAGGGT		 GGGGGCTGGGTTAGAAGCAT	
D7 CTTGCAGGGAGGTTGCTCCT	 TTCTCAGAGTGCAGCCGGTG	
D8 GAGCCTGGCAATTGCTTGTCATT	 GGGGTAAAGCCGCTTTCCTCT		
D9 GCCACTTGCTTTTCTTTGCAGAGA		 AAGCTTGGCATTCCGGTACTGT	
MYCNp_-1252;-1045	 TTTGGTACCGGAAGGGAAGGGGCCAAT		 TTTGAGCTCTCACTACTTCGTTTCTTTGTGCC	
MYCNp_-335;-133	 TTTGGTACCGCAGGGTGGGTGCTGCATT	 TTTGAGCTCGCCCTCCTGATTTCCATAAAAATCAGGGG	
MYCNp_-187;-2	 TTTGGTACCTTTTGGCGCGAAAGCCTTGG	 TTTGCTAGCGGATCACTACTTGTCAT	
MYCNp_E2F1/E2F2	 AAGCCACTTGCTTTTCTTTGCAGAGAGAAG	 GCCTTGGCGCCTCCCCTGATTTTT	
MYCNp_E2F3/TIE	 TTTCGCGCCAAAAGCCACTTGCTTT	 CCCCTGATTTTTATGGAAATCAGGAGG		
MYCNp_E2Fs/TIE	 AAGCCACTTGCTTTTCTTTGCAGAGAGAAG	 CCCCTGATTTTTATGGAAATCAGGAGG		
 
CH-IP CHROMATIN IMMUNOPRECIPITATION 
Chromatin immunoprecipitation were performed on M606 treated neuroblastoma cells and 
thus the specific protocol is intended for treated human neuroblastoma cells growing 
adhesively. One of the critical steps in ChIP regards the chromatin fragmentation 
conditions, which need to be experimentally determine for each cell types used. 
Count and centrifuge 1x10^7 cells for each IP points and resuspend in 10mL of DMEM (if 
M606 was added to cells prior experiment, add DMEM with M606 addition again). Add 
270 µL of formaldehyde from a 37% and incubate RT rotating at 13rpm for 10min. Add 
0,5 ml of glycine from a 2,5 M stock solution mix rapidly and incubate RT rotating at 
13rpm for 10min. centrifuge 5min 1500rpm at 4°C then keep sample on ice. Remove 
supernatant and add 10mL of PBS1X washing cells for 3 times centrifuging for 5min 
1500rpm at 4°C. Add 0,5mL of ice-cold Cell Lysis Buffer to the pellet and gently mix 
tube. Centrifuge 10min 3000rpm at 4°C and remove supernatant. Add to pellet 200 µL ice-
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cold RIPA buffer with SDS 0,7% and mix. Incubate 20min on ice. Sonicate 2 times for 
15sec at low power and 5 times for 15sec at high power mixing samples after each sonicate 
cycle. Sonicate preclearing: centrifuge samples 15min at 14000 rpm at 4°C and transfer 
supernatant in a new tube containing 30 µL of beads coated with Immobilized Protein A. 
Incubate 30min 13rpm in rotation at 4°C. Spin down 5min 3000 rpm at 4°C. Transfer the 
supernatant in a new fresh tube end, after putting aside 30 µL for INPUT DNA 
preparation, add 5 µgr of specific antibody. Incubate O/N 13rpm in rotation at 4°C. For 
input DNA preparation, dilute to 100 µL with RIPA wash and store at -20°C. The day 
after, add to sample 30 µL of coated beads and incubate 30min 13rpm in rotation RT then 
centrifuge 3min 3000rpm 15°C and proceed with the following washing steps: twice with 
1mL RIPA wash; 3 times with 1mL Washing buffer; twice with 1mL TE buffer always 
rotating 3min RT and spin down 3min 3000rpm 15°C. Recover the supernatant and add 70 
µL of  TE buffer to the beads and also to the input and add RNAse A 10 µgr and incubate 
1hour 1000rpm at 37°C. Add 20 µl Proteinase 74 K Buffer 5X and 6 µl Proteinase K (19 
mg/mL) and incubate 6hours 950 rpm at 65°C. Centrifuge 10min at 6000 rpm at 4°C and 
transfer the supernatant to a Phase Lock gel tube. Add same volume of 
phenol/chlorophorm/isoamylalcohol mix and centrifuge 3min 13000rpm RT. Transfer 
aqueous phase into a new tube and add 1/10 of Na acetate 3M pH 5.2, 1 µL glycogen from 
a 20 mg/mL stock solution and 2,5v of EtOH then vortex and let DNA precipitate O/N at -
2’°C. The day after centrifuge 30min 13000rpm at 4°C then wash pellet twice with 1mM 
of EtOH 70%. Resuspend pellet of IP-DNA and input sample in 50uL of water and 
quantify input to create proper dilution at 1 µgr/µL. Use 2-4 µl of IP-DNA for Real Time 
PCR analysis. 
Buffers used are listed below: 
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METHYLATED DNA IMMUNOPRECIPITATION  
Methylated DNA immunoprecipitation were performed on M606 treated neuroblastoma 
cells and thus the specific protocol is intended for treated human neuroblastoma cells 
growing adhesively. One of the critical steps in ChIP regards the chromatin fragmentation 
conditions, which need to be experimentally determine for each cell types used. 
Genomic extraction was performed using 5prime kit. 20 µgr of genomic DNA were used 
for each IP point in a final volume of 300 µL of FB buffer 1X. Perform 3 sonication at 
high power for 10min and then denature DNA at 98°C for 15min and put on ice. Add 50 
µgL of pre-cleared beads (pre-incubated with salmon sperm for 4 hours, washed 3 times 
with 1mL of FB and after centrifuge 2min 3000rpm RT resuspended in half of initial 
volume) and incubate on wheel 15min 4°C. Spin down 1min 14000rpm for 4°C and 
transfer supernatant into a new tube. Split sample in input 20 µL and MeC: 270 µL and 
330 µL of FB buffer 1X. Add 10 µgr of antibody anti-MeC and incubate O/N on wheel at 
4°C. The day after, add 50 µL of coated beads to sample and incubate rotating 30min RT.  
Immunoprecipitate sample spinning 4000rpm 5min and discard supernatant. Wash pellet 4 
times with FB1X and twice with TE buffer spinning each time 2min 4000 RT after 2min of 
incubation on wheel. Resuspend pellet in 70 µL of TE and proceed with RNAse and 
Proteinase K treatment as for ChIP. Precipitation with phenol/chlorophorm/isoamylalcohol 
was performed as for ChIP. Primers used for ChIP and MeDIP: 
TSS	FW	MYCNp	 GCCTTCTCTCTGCAAAGAAAAGC	
TSS	RV	MYCNp	 AAGGAGAGGAAAGCGGCTTTAC	
	-400	FW	MYCNp	 GCGCCCCTCTTCTTTCAATTTG	
	-400	RV	MYCNp	 ACGAAAGAAGGGTAGTCCGAAG	
	-1400	FW	MYCNp	 ATCCAATGGTGAGGTGAAGAGG	
	-1400	RV	MYCNp	 TCCTTAGGCTTGTTTGGAGAGAG	
500	FW	MYCNp	 GGACTGTTTCTGCTTCCGAAAC	
500	RV	MYCNp	 GTAAGGGCTGCAAAAGGATTAGG	
1500	FW	MYCNp	 TGTCTGTCGGTTGCAGTGTTG	
1500	RV	MYCNp	 TCCGCCCCGTTCGTTTTAATAC	
TSS	FW	GAPDH	 GGCTACTAGCGGTTTTACGGG	
TSS	RV	GAPDH	 GCTGCGGGCTCAATTTATAGAAACC		
	-400	FW	GAPDH	 CTGAGCAGTCCGGTGTCACTAC	
	-400	REV	GAPDH	 CCTCCCCTTTCTTTCTTTCAA	
1500	FW	GAPDH	 TCCTGATTTCTGGAAAAGAGCTA	
1500	REV	GAPDH	 GGAAGAGGGGAAGCTGTATTTTA	
LDH	TSS	FW	 GCGTTTCATTACCACCCTCT	
LDH	TSS	REV	 GTCCAGATCACCGAATGCT	
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STATISTICAL ANALYSIS 
All experiments are performed at least 3 times. Data were analyzed with Graphpad Prism 6 
software and expressed as mean ± standard deviation (SD). Analysis of Variance 
(ANOVA) among groups was used to analyze difference among groups. two-sided 
unpaired t test was used for two groups. Survival analyses and two genes correlation were 
performed according to the method of Kaplan and Meier and two-sided log-rank tests 
(193). A probability value of 0.05 or less was considered statistically significant.  
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